var title_f39_11_40112="Irritant contact derm PI";
var content_f39_11_40112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Irritant contact dermatitis usually affects the hands. It causes the skin to turn red and dry, and to chap and crack.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40112=[""].join("\n");
var outline_f39_11_40112=null;
var title_f39_11_40113="Nail tangential excision";
var content_f39_11_40113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Nail tangential excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40113=[""].join("\n");
var outline_f39_11_40113=null;
var title_f39_11_40114="Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)";
var content_f39_11_40114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16965\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/55/13168\">",
"         Upper digestive system in a child",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/7/30843\">",
"          Medicines used to treat acid reflux",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/24/43394\">",
"         Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/50/32547\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/16/16643\">",
"         Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/acid-reflux-gastroesophageal-reflux-disease-in-children-and-adolescents-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2271532\">",
"      <span class=\"h1\">",
"       What is acid reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Acid reflux (also called &ldquo;gastroesophageal reflux&rdquo; or just &ldquo;reflux&rdquo;) is when the acid that is normally in the stomach backs up into the esophagus (",
"      <a class=\"graphic graphic_figure graphicRef52952 \" href=\"mobipreview.htm?12/55/13168\">",
"       figure 1",
"      </a>",
"      ). The esophagus is the tube that carries food from the mouth to the stomach.",
"     </p>",
"     <p>",
"      A small amount of acid reflux is normal. But if the reflux happens frequently, it can cause problems with the esophagus or lung infections (pneumonia). Reflux that has become more serious is called &ldquo;gastroesophageal reflux disease,&rdquo; or GERD.",
"     </p>",
"     <p>",
"      Children with certain health issues have a higher risk of getting reflux. These include children with Down syndrome, cerebral palsy, or other problems with the brain or spinal cord. Children who are overweight also are more likely to have reflux.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2271539\">",
"      <span class=\"h1\">",
"       What are the symptoms of acid reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the child&rsquo;s age.",
"     </p>",
"     <p>",
"      Preschool children with acid reflux might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vomit",
"       </li>",
"       <li>",
"        Taste stomach acid in the mouth, or feel it in the throat",
"       </li>",
"       <li>",
"        Not want to eat",
"       </li>",
"       <li>",
"        Lose weight",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Older children or adolescents with acid reflux might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taste stomach acid in the mouth, or feel it in the throat",
"       </li>",
"       <li>",
"        Have an upset stomach",
"       </li>",
"       <li>",
"        Feel burning in the chest (known as &ldquo;heartburn&rdquo;)",
"       </li>",
"       <li>",
"        Have trouble swallowing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Having symptoms like these once in a while is normal. If any of these symptoms happen more than once a week, this might be a sign of GERD.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2271546\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you think your child might have acid reflux, talk to his or her doctor or nurse before you try any treatments. He or she can suggest ways to help relieve symptoms. He or she might also do tests to figure out if your child&rsquo;s symptoms are caused by reflux or something else.",
"     </p>",
"     <p>",
"      Take your child to see a doctor or nurse",
"      <strong>",
"       right away",
"      </strong>",
"      if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has trouble swallowing, or feels as though food gets &ldquo;stuck&rdquo; on the way down",
"       </li>",
"       <li>",
"        Loses weight",
"       </li>",
"       <li>",
"        Has chest pain",
"       </li>",
"       <li>",
"        Chokes when he or she eats",
"       </li>",
"       <li>",
"        Vomits blood",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2271553\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are some things that might help with acid reflux, depending on your child&rsquo;s age and symptoms. Your child&rsquo;s doctor or nurse might suggest that you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid giving your child foods that make symptoms worse (examples include chocolate, peppermint, and fatty foods)",
"       </li>",
"       <li>",
"        Raise the head of your child&rsquo;s bed by 6 to 8 inches (for example, by putting blocks of wood under 2 legs of the bed or a Styrofoam wedge under the mattress). Do",
"        <strong>",
"         not",
"        </strong>",
"        raise the head of an infant&rsquo;s crib or bed.",
"       </li>",
"       <li>",
"        Help your child to lose weight, if he or she is overweight (ask your child&rsquo;s doctor or nurse for advice on how to do this)",
"       </li>",
"       <li>",
"        Keep your child away from cigarette smoke",
"       </li>",
"       <li>",
"        Have your child avoid lying down for a few hours after a meal",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2271560\">",
"      <span class=\"h1\">",
"       How is acid reflux treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most times, acid reflux symptoms can be treated with medicines. There are three main types of medicines that can help: antacids, histamine blockers, and proton pump inhibitors (",
"      <a class=\"graphic graphic_table graphicRef78918 \" href=\"mobipreview.htm?30/7/30843\">",
"       table 1",
"      </a>",
"      ). All of these medicines work by reducing or blocking stomach acid. But they each do that in a different way:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antacids can relieve mild symptoms, but they work only for a short time. You can buy them without a prescription. Children younger than school age should",
"        <strong>",
"         not",
"        </strong>",
"        take antacids.",
"       </li>",
"       <li>",
"        Histamine blockers are stronger and last longer than antacids. You can also buy most histamine blockers without a prescription.",
"       </li>",
"       <li>",
"        Proton pump inhibitors are the most effective medicines in treating GERD. You can buy two of these medicines without a prescription. But there are other versions that your child&rsquo;s doctor or nurse can prescribe.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you child&rsquo;s doctor or nurse recommends a medicine, he or she will usually suggest that your child try the medicine for a few weeks first. Then if symptoms do not get better, the doctor or nurse might suggest a different medicine, or decide to do tests.",
"     </p>",
"     <p>",
"      Sometimes acid reflux medicines are less expensive if you get them with a prescription. Other times nonprescription medicines are less expensive. If cost is a concern for you, ask your pharmacist how you might reduce the cost of your child&rsquo;s medicines.",
"     </p>",
"     <p>",
"      Talk to your child&rsquo;s doctor or nurse before you give your child",
"      <strong>",
"       any",
"      </strong>",
"      medicines for reflux.",
"     </p>",
"     <p>",
"      A few children need surgery to treat their GERD. This is more likely in children who have a problem with the brain or spinal cord (such as cerebral palsy), and if the GERD is causing problems like pneumonia. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2271619\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/24/43394?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/11/40114?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16965 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40114=[""].join("\n");
var outline_f39_11_40114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271532\">",
"      What is acid reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271539\">",
"      What are the symptoms of acid reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271546\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271553\">",
"      Is there anything I can do to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271560\">",
"      How is acid reflux treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271619\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/55/13168\">",
"      Upper digestive system in a child",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/7/30843\">",
"       Medicines used to treat acid reflux",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/24/43394?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40115="Long axis MV annular calcium";
var content_f39_11_40115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral annular calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anatomical specimen (panel A) is sectioned along the long axis of the heart; the infiltrative calcific process just beneath the posterior mitral valve (pML) is called mitral annular calcification (MAC) or subannular calcification. The latter term is probably preferable because the process actually infiltrates the posterior wall (PW) myocardium. In this case, the infiltration extends nearly halfway through the basal myocardium and nearly one third of the way to the papillary muscle (PM). The long axis echocardiogram from a patient with mitral annular calcification (panel B) shows that the image faithfully represents the pathologic process; MAC extends at least one-third of the way from the mitral annulus to the PM base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40115=[""].join("\n");
var outline_f39_11_40115=null;
var title_f39_11_40116="Zopiclone: Patient drug information";
var content_f39_11_40116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zopiclone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/24/17798?source=see_link\">",
"     see \"Zopiclone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F236316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Zopiclone&reg;;",
"     </li>",
"     <li>",
"      CO Zopiclone;",
"     </li>",
"     <li>",
"      Dom-Zopiclone;",
"     </li>",
"     <li>",
"      Imovane&reg;;",
"     </li>",
"     <li>",
"      Mylan-Zopiclone;",
"     </li>",
"     <li>",
"      Novo-Zopiclone;",
"     </li>",
"     <li>",
"      Nu-Zopiclone;",
"     </li>",
"     <li>",
"      PHL-Zopiclone;",
"     </li>",
"     <li>",
"      PMS-Zopiclone;",
"     </li>",
"     <li>",
"      PRO-Zopiclone;",
"     </li>",
"     <li>",
"      RAN&trade;-Zopiclone;",
"     </li>",
"     <li>",
"      ratio-Zopiclone;",
"     </li>",
"     <li>",
"      Rhovane&reg;;",
"     </li>",
"     <li>",
"      Riva-Zopiclone;",
"     </li>",
"     <li>",
"      Sandoz-Zopiclone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15837783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703153",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zopiclone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3448673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad liver disease, very bad lung disease, myasthenia gravis, or sleep apnea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take naps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take when you have trouble falling asleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12017 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40116=[""].join("\n");
var outline_f39_11_40116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236316\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15837783\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013317\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013316\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013321\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013322\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013324\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013319\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013320\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013325\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013326\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/24/17798?source=related_link\">",
"      Zopiclone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40117="Oxybutynin: Pediatric drug information";
var content_f39_11_40117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxybutynin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"    see \"Oxybutynin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/47/35574?source=see_link\">",
"    see \"Oxybutynin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Gelnique 3%&trade;;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Oxytrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxybutynin&reg;;",
"     </li>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Dom-Oxybutynin;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Mylan-Oxybutynin;",
"     </li>",
"     <li>",
"      Novo-Oxybutynin;",
"     </li>",
"     <li>",
"      Nu-Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutynine;",
"     </li>",
"     <li>",
"      Oxytrol&reg;;",
"     </li>",
"     <li>",
"      PHL-Oxybutynin;",
"     </li>",
"     <li>",
"      PMS-Oxybutynin;",
"     </li>",
"     <li>",
"      Riva-Oxybutynin;",
"     </li>",
"     <li>",
"      Uromax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Urinary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"      see \"Oxybutynin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-5 years: 0.2 mg/kg/dose 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;5 years: 5 mg twice daily, up to 5 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: &ge;6 years: 5 mg once daily; increase as tolerated in 5 mg increments to a maximum of 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 5 mg 2-3 times/day up to 5 mg 4 times/day maximum",
"     <b>",
"      or",
"     </b>",
"     extended release tablet (Ditropan&reg; XL) 5-10 mg once daily; increase in 5 mg increments to a maximum of 30 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical gel: Apply contents of one sachet (100 mg/g) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: 3.9 mg/day system applied twice weekly (every 3-4 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Should be discontinued periodically to determine whether the patient can manage without the drug and to minimize tolerance to the drug",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique 3%&trade;: 3% (92 g) [contains ethanol; delivers oxybutynin 28 mg/pump actuation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique&reg;: 10% (1 g) [contains ethanol; oxybutynin chloride 100 mg/1 g sachet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxytrol&reg;: 3.9 mg/24 hours (8s) [39 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total oxybutynin 36 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as chloride: 5 mg/5 mL (5 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as chloride: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ditropan XL&reg;: 5 mg, 10 mg, 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel, transdermal patch",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16057118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxytrol&reg; for Women: FDA approved January 2013; availability anticipated in the fall of 2013. Oxytrol&reg; for Women is an over-the-counter (OTC) transdermal patch indicated for the treatment of overactive bladder.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without food; swallow extended release tablets whole; do not chew or crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel: For topical use only. Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders. Rotate site; do not apply to same site on consecutive days. Wash hands after use. Cover treated area with clothing after gel has dried to prevent transfer of medication to others. Do not bathe, shower, or swim until 1 hour after gel applied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal: Apply to dry intact skin on the abdomen, hip, or buttock. Rotate site of application with each administration and avoid application to the same site within 7 days",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; protect syrup from light; keep transdermal patch in sealed pouch; protect from moisture or humidity; keep gel in sachet; protect from heat.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of bladder spasms associated with voiding in patients with uninhibited and reflex neurogenic bladder; treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in ages &gt;5 and adults); symptoms of detrus or overactivity associated with a neurological condition (XL product FDA approved in ages &gt;6 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oxybutynin may be confused with OxyCONTIN&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ditropan may be confused with Detrol&reg;, diazepam, Diprivan&reg;, dithranol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (sinus), blood pressure change (increased/decreased), chest pain, edema, flushing, palpitation, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, fatigue, headache, insomnia, nervousness, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dry skin, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal taste, constipation, diarrhea, dry throat, dyspepsia, dysphagia, eructation, flatulence, gastrointestinal reflux disease, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis, dysuria, pollakiuria, urinary hesitation, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, extremity pain, flank pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, dry eyes, eye irritation, keratoconjunctivitis sicca",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, bronchitis, cough, hoarseness, nasal congestion, nasal dryness, nasopharyngitis, pharyngolaryngeal pain, sinus congestion, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fungal infection, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, anorexia, cycloplegia, dysphonia, GI motility decreased, glaucoma, hallucinations, hypersensitivity reactions, impotence, lactation suppression, memory impairment, mydriasis, psychotic disorder, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, seizures, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Topical gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Constipation, gastroenteritis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Application site reaction (includes anesthesia, dermatitis, erythema, irritation, pain, papules, pruritus)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction, erythema, pruritus, rash, vesicles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision changes",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Cardiac arrhythmia, cycloplegia, hallucinations, impotence, lactation suppressed, myocarditis, seizure, sweating decreased, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxybutynin or any component; glaucoma (angle-closure), partial or complete GI obstruction, GU obstruction; toxic megacolon",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal disease, myasthenia gravis, heart disease, hyperthyroidism, reflux esophagitis, hypertension, prostatic hypertrophy, autonomic neuropathy, ulcerative colitis, intestinal atony. After application of the alcohol-based gel product, avoid open fire or smoking until gel has dried. Once topical gel has dried, application site should be covered with clothing to avoid transfer of medicine to others.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4045394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may slightly delay absorption and increase bioavailability of immediate release formulation by 25%. Absorption of extended release formulation is not affected by food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle; does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void resulting in decreased urgency and frequency",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Oral: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release formulation: Maximum effects: 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal formulation: Duration: 96 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 193 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via cytochrome isozyme CYP3A4 found mostly in liver and gut wall; extensive first pass effect (not with I.V. or transdermal use); metabolized in the liver to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Immediate release: 6% (range: 1.6% to 10.9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Within 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;0.1% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/47/35574?source=see_link\">",
"      see \"Oxybutynin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause heat prostration (fever and heat stroke due to decreased sweating) when used in hot climates; avoid alcohol; may cause dry mouth; nonabsorbable tablet shell may be seen in stool, but active drug has been released",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Humphreys MR and Reinberg YE, \"Contemporary and Emerging Drug Treatments for Urinary Incontinence in Children,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2005, 7(3):151-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40117/abstract-text/15977961/pubmed\" id=\"15977961\" target=\"_blank\">",
"        15977961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12665 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-518C2F532B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40117=[""].join("\n");
var outline_f39_11_40117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204694\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204695\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060756\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060750\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057118\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060759\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060753\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060758\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204742\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204740\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060763\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060749\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4045394\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204730\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204662\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060764\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204677\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060761\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060762\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060755\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=related_link\">",
"      Oxybutynin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/47/35574?source=related_link\">",
"      Oxybutynin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40118="Therapeutic use of ibutilide";
var content_f39_11_40118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use of ibutilide",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40118/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/11/40118/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is a class III antiarrhythmic drug available only for intravenous use for the termination of atrial arrhythmias. An oral form is not available because of extensive first-pass metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiology and pharmacology of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    use and the side effects that can occur will be reviewed here. The pharmacokinetics of ibutilide, drug interactions, and the various clinical settings in which ibutilide might be used are discussed in detail separately. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     \"Ibutilide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106434424\">",
"    <span class=\"h2\">",
"     Cellular mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other class III antiarrhythmic agents (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    prolongs repolarization in atrial and ventricular myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The class III drugs block IKr, the rapid component of the cardiac delayed rectifier potassium current. This results in prolonged repolarization, increased action potential duration, and lengthening of the refractory period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/1\">",
"     1",
"    </a>",
"    ]. Ibutilide increases the refractoriness of atrial and ventricular myocardium, the atrioventricular node, His-Purkinje system, and accessory pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, ibutilide activates a slow, delayed inward sodium current that occurs early during repolarization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Major side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106434431\">",
"    <span class=\"h2\">",
"     Effects on the ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    has two major effects on the electrocardiogram (ECG): it produces mild slowing of the sinus rate and, as with other class III antiarrhythmic drugs, prolongation of the QT interval. There is no effect on the PR interval or QRS duration.",
"   </p>",
"   <p>",
"    The degree of QT prolongation associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    is related to the dose, the rate of infusion, and the serum concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/5\">",
"     5",
"    </a>",
"    ]. Prolongation of the QT interval provides the substrate for torsades de pointes (TdP), a polymorphic ventricular tachycardia. The QT interval returns to baseline within two to four hours after stopping the infusion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Proarrhythmia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5117694\">",
"     'Discontinuing ibutilide infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106434349\">",
"    <span class=\"h2\">",
"     Mechanism of proarrhythmic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other drugs that prolong the QT interval and cause torsades de pointes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    blocks IKr, the rapid component of the delayed rectifier potassium current that is responsible for phase 3 depolarization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/6\">",
"     6",
"    </a>",
"    ]. IKr results from a heteromeric complex formed by a tetrameric potassium channel encoded by the HERG gene (KCNH2) in complex with an accessory subunit encoded by the MirP1 gene (KCNE2). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H3#H3\">",
"     \"Acquired long QT syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    exhibits \"reverse use dependence\", which is defined as an inverse correlation between the heart rate and QT interval. As a result, the QT interval decreases as the heart rate increases and lengthens as the heart rate slows. This explains why drug-induced polymorphic ventricular tachycardia (VT) is more commonly seen with bradycardia.",
"   </p>",
"   <p>",
"    The effect of heart rate may be mediated by changes in the local extracellular potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/7\">",
"     7",
"    </a>",
"    ]. Lower heart rates result in less potassium moving out of the cell during repolarization (before subsequent reuptake by the Na-K-ATPase pump), since there are fewer repolarizations. The associated reduction in extracellular potassium concentration enhances the degree of drug-induced inhibition of IKr, increasing the QT interval. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    has a half-life of 2 to 12 hours. It is extensively metabolized by the liver to eight metabolites. Only one metabolite exhibits antiarrhythmic activity, but its level is only approximately 10 percent of the parent drug level. As a result, this metabolite plays no role in the efficacy of ibutilide. Although almost 90 percent of the drug or its metabolites are detected in the urine, only 7 percent is excreted as the native, active drug. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     \"Ibutilide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117183\">",
"    <span class=\"h1\">",
"     CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset. Since there is no oral preparation of ibutilide, it has no role in the long-term prevention of these arrhythmias. Ibutilide is not approved for the treatment of ventricular arrhythmias, and its efficacy for these arrhythmias is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117190\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 Practice Guidelines from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    concluded that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    is useful and effective for the pharmacologic cardioversion of recent onset atrial fibrillation (",
"    <a class=\"graphic graphic_table graphicRef71524 graphicRef59778 \" href=\"mobipreview.htm?28/37/29277\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/8\">",
"     8",
"    </a>",
"    ]. As with other antiarrhythmic drugs, the efficacy of ibutilide is greatest when the atrial fibrillation is of short duration (",
"    <a class=\"graphic graphic_figure graphicRef62459 \" href=\"mobipreview.htm?22/18/22829\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While it is of clear benefit in atrial fibrillation that has been present for seven days or less, the evidence is less robust but also suggests efficacy for atrial fibrillation of more than seven days duration. Most patients studied had arrhythmia for less than 90 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Similar efficacy has not been demonstrated with arrhythmia duration exceeding 90 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701784#H8701784\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Ibutilide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for pharmacologic cardioversion of atrial fibrillation and the settings in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    might be used are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the general use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    for cardioversion of atrial fibrillation, it has also been used in specific settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As pretreatment before electrical cardioversion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701669#H8701669\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Pretreatment with antiarrhythmic drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To convert atrial fibrillation to sinus rhythm in patients with Wolff-Parkinson-White syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=see_link&amp;anchor=H10#H10\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\", section on 'Acute therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To convert atrial fibrillation to sinus rhythm after cardiac surgery or cardiac transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117243\">",
"    <span class=\"h2\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    is effective for the cardioversion of atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/9-11,15\">",
"     9-11,15",
"    </a>",
"    ], including atrial flutter that occurs after cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117303\">",
"    <span class=\"h2\">",
"     Combination ibutilide plus esmolol for recent onset atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    has a short half-life, which makes it appealing for use in the acute conversion of atrial fibrillation. A randomized, prospective study comparing the combination of intravenous esmolol plus ibutilide with ibutilide monotherapy for conversion of recent-onset atrial fibrillation with a rapid ventricular rate showed improvement in the rate of conversion to sinus rhythm in the combined",
"    <span class=\"nowrap\">",
"     ibutilide/esmolol",
"    </span>",
"    group (67 percent with the combination versus 46 percent for ibutilide monotherapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/16\">",
"     16",
"    </a>",
"    ]. The slower the ventricular rate at the time of ibutilide administration, the greater was the probability of conversion to sinus rhythm. In addition, there was a marked reduction in the incidence of immediate atrial fibrillation recurrence in the group receiving both esmolol and ibutilide. The",
"    <span class=\"nowrap\">",
"     ibutilide/esmolol",
"    </span>",
"    combination was also associated with a lower risk of torsade de pointes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117310\">",
"    <span class=\"h2\">",
"     Ibutilide in children and in patients with congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    for cardioversion of atrial flutter and atrial fibrillation in children and in patients with congenital heart disease was reviewed in a report of 19 patients, age 6 months to 34 years (median 16 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/17\">",
"     17",
"    </a>",
"    ]. Ibutilide successfully restored sinus rhythm in 71 percent of arrhythmia episodes, with success during the first administration in 12 of 19 (63 percent). Fourteen episodes in six patients required electrical cardioversion after ibutilide failed. There were no episodes of symptomatic bradycardia, and only one episode each of polymorphic and monomorphic ventricular tachycardia. With careful monitoring, ibutilide can be effective for children and young patients with congenital heart disease for cardioversion of atrial arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16281208\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16281136\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    varies with patient size:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients weighing",
"      <strong>",
"       less than 60 kg",
"      </strong>",
"      , the dose is 0.01",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused over 10 minutes. If the arrhythmia does not terminate within 10 minutes after the end of the infusion, a second bolus (same dose over 10 minutes) may be given.",
"     </li>",
"     <li>",
"      For patients weighing",
"      <strong>",
"       more than 60 kg",
"      </strong>",
"      , the dose is 1 mg over 10 minutes. Again, if the arrhythmia does not terminate within 10 minutes after the end of the infusion, a second bolus of 1 mg over 10 minutes may be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16281169\">",
"    <span class=\"h2\">",
"     Role of magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    enhances the ability of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    to successfully convert atrial fibrillation or flutter, and it can attenuate the QT interval prolongation associated with ibutilide therapy. Two cohort studies have shown that the concurrent administration of magnesium (doses of four to five grams administered intravenously) with ibutilide is associated with a greater chance of successful chemical conversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. One of the two studies also reported a significantly lower rate of polymorphic ventricular tachycardia in patients who received the",
"    <span class=\"nowrap\">",
"     magnesium/ibutilide",
"    </span>",
"    combination compared to patients who received only ibutilide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MAJOR SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    are infrequent and typically transient. In one report, the only noncardiac side effects that occurred more frequently than with placebo were nausea (1.9 percent), headache (3.6 percent), and renal failure (0.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/9\">",
"     9",
"    </a>",
"    ]. The most serious side effects are those involving the cardiovascular system. As a result, ibutilide should not be used in patients with severe structural cardiac disease, prolonged QT interval, or underlying sinus node disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proarrhythmia, particularly nonsustained or sustained polymorphic (torsades de pointes) or monomorphic ventricular tachycardia (VT), is the most important toxic reaction. Because of the risk of ventricular tachycardia, particularly torsades de pointes, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    should be observed with continuous ECG monitoring for at least four hours after the infusion is finished and longer if needed until the QTc interval has returned to baseline.",
"   </p>",
"   <p>",
"    In several large series, polymorphic VT was seen in between four and eight percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/10,11,15,20\">",
"     10,11,15,20",
"    </a>",
"    ]. Sustained episodes requiring cardioversion were seen in approximately two percent of patients. In addition to polymorphic VT, nonsustained monomorphic VT occurred in three to four percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The majority of episodes of sustained polymorphic VT occurred within ten minutes of the first dose (before the second dose would be given, if necessary).",
"   </p>",
"   <p>",
"    Torsades de pointes may be more common in women, occurring in six percent of women in one series (versus three percent of men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the risk was increased in patients with heart failure (eleven percent versus four percent in those without heart failure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Class IC antiarrhythmic drugs, which slow conduction by blocking sodium channels, also have the potential for proarrhythmia. However, since class IC drugs do not cause QT prolongation, it has also been suggested these drugs can be used safely with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    . In two reports including a total of 175 patients with atrial fibrillation or atrial flutter, 150 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    and 25 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. All were treated with ibutilide up to 2 mg, which was successful in restoring sinus rhythm in 62 percent. Only two patients developed nonsustained polymorphic VT with one developing sustained polymorphic VT (two percent of patients), a rate consistent with that seen in patients not taking a class IC antiarrhythmic drug.",
"   </p>",
"   <p>",
"    The potential for polymorphic VT is increased in patients who are being treated with another drug that prolongs the QT interval. However, the risk of proarrhythmia does not appear to be increased when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    is given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other cardiac toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    has been associated with a number of cardiac side effects other than proarrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension &ndash; 2 percent. Usually the degree of hypotension is mild and responds to fluid resuscitation.",
"     </li>",
"     <li>",
"      Sinus tachycardia or supraventricular tachycardia &ndash; 2.7 percent.",
"     </li>",
"     <li>",
"      Sinus bradycardia &ndash; 1.2 percent.",
"     </li>",
"     <li>",
"      Atrioventricular block &ndash; 1.5 percent.",
"     </li>",
"     <li>",
"      Bundle branch block &ndash; 1.9 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the above arrhythmias and conduction changes have been reported transient with minimal or no associated symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemodynamic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     Ibutilide",
"    </a>",
"    produces no clinically significant changes in left ventricular function or hemodynamics, including mean pulmonary artery pressure or pulmonary capillary wedge pressure, even in patients with reduced left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5117694\">",
"    <span class=\"h2\">",
"     Discontinuing ibutilide infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients who respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , arrhythmia termination is seen within 40 to 60 minutes after beginning the infusion (mean 27 to 33 minutes in two studies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40118/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. The infusion should be stopped for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presenting arrhythmia is terminated",
"     </li>",
"     <li>",
"      The patient develops ventricular tachycardia (sustained or nonsustained)",
"     </li>",
"     <li>",
"      The patient develops marked prolongation of the QT interval (to a corrected QT interval &gt;500 msec with narrow QRS, or corrected QT &gt;550 msec in patients with bundle branch block)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92369783\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       Ibutilide",
"      </a>",
"      , a class III antiarrhythmic drug, blocks IKr, the rapid component of the cardiac delayed rectifier potassium current. This results in prolonged repolarization, increased action potential duration, and lengthening of the refractory period. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       Ibutilide",
"      </a>",
"      has two major effects on the electrocardiogram (ECG): it produces mild slowing of the sinus rate and, as with other class III antiarrhythmic drugs, prolongation of the QT interval. There is no effect on the PR interval or QRS duration. Prolongation of the QT interval provides the substrate for torsades de pointes (TdP), a polymorphic ventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       Ibutilide",
"      </a>",
"      is approved for the acute termination of atrial fibrillation and atrial flutter and is most useful and effective for the pharmacologic cardioversion of atrial fibrillation less than or equal to seven days duration. (See",
"      <a class=\"local\" href=\"#H5117190\">",
"       'Atrial fibrillation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5117243\">",
"       'Atrial flutter'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701784#H8701784\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Ibutilide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proarrhythmia, particularly nonsustained or sustained polymorphic ventricular tachycardia (VT) (torsades de pointes) or monomorphic VT, is the most important toxicity associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      . Because of the risk of VT, particularly torsades de pointes, patients treated with ibutilide should be observed with continuous ECG monitoring for at least four hours after the infusion is finished, or until the QTc interval has returned to baseline. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Proarrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      infusion should be stopped for the following reasons (see",
"      <a class=\"local\" href=\"#H5117694\">",
"       'Discontinuing ibutilide infusion'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presenting arrhythmia is terminated",
"     </li>",
"     <li>",
"      The patient develops VT (sustained or nonsustained)",
"     </li>",
"     <li>",
"      The patient develops marked prolongation of the QT interval",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/1\">",
"      Murray KT. Ibutilide. Circulation 1998; 97:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/2\">",
"      Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992; 222:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/3\">",
"      Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001; 104:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/4\">",
"      Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/5\">",
"      Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993; 22:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/6\">",
"      Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995; 91:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/7\">",
"      Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996; 93:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/8\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/9\">",
"      Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/10\">",
"      Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996; 28:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/11\">",
"      Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J 1998; 136:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/12\">",
"      Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001; 103:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/13\">",
"      VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/14\">",
"      Tallaj JA, Franco V, Rayburn BK, et al. Safety and efficacy of ibutilide in heart transplant recipients. J Heart Lung Transplant 2009; 28:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/15\">",
"      Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/16\">",
"      Fragakis N, Bikias A, Delithanasis I, et al. Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace 2009; 11:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/17\">",
"      Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol 2007; 30:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/18\">",
"      Tercius AJ, Kluger J, Coleman CI, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 2007; 30:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/19\">",
"      Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol 2010; 106:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/20\">",
"      Gowda RM, Khan IA, Punukollu G, et al. Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol 2004; 95:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/21\">",
"      Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol 2004; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/22\">",
"      Hongo RH, Themistoclakis S, Raviele A, et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004; 44:864.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bionichepharmausa.com/pdf/Ibutilide_Fumarate_PI.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40118/abstract/24\">",
"      Stambler BS, Beckman KJ, Kadish AH, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997; 80:458.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 924 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40118=[""].join("\n");
var outline_f39_11_40118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H92369783\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106434424\">",
"      Cellular mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106434431\">",
"      Effects on the ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106434349\">",
"      Mechanism of proarrhythmic effect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5117183\">",
"      CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5117190\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5117243\">",
"      Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5117303\">",
"      Combination ibutilide plus esmolol for recent onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5117310\">",
"      Ibutilide in children and in patients with congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16281208\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16281136\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16281169\">",
"      Role of magnesium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MAJOR SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other cardiac toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5117694\">",
"      Discontinuing ibutilide infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92369783\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/924|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/18/22829\" title=\"figure 1\">",
"      Ibutilide sotalol duration AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/30/24044\" title=\"table 2A\">",
"      ACC AHA ESC revert AF before 7d",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/7/20604\" title=\"table 2B\">",
"      ACC AHA ESC revert AF after 7d",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=related_link\">",
"      Ibutilide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40119="Approach to the initially stable child with blunt or penetrating injury";
var content_f39_11_40119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the initially stable child with blunt or penetrating injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Lois K Lee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40119/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/11/40119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to the management of the stable child who has sustained traumatic injury is reviewed here. Trauma management in the unstable child is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For this review, the stable pediatric trauma patient refers to an injured child who initially has normal or near normal vital signs, normal vital functions (airway, breathing, circulation, mental status), and no readily apparent critical injury. It is imperative for the trauma provider to use normative values for children as opposed to adults when assessing vital signs (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"mobipreview.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3477?source=see_link\">",
"     \"Trauma management: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many seriously injured children, who ultimately require hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical intervention initially appear stable. It is incumbent on the emergency provider to thoroughly evaluate initially stable appearing traumatized children and to identify those at high risk for serious injury based on mechanism and physical findings (",
"    <a class=\"graphic graphic_table graphicRef60424 \" href=\"mobipreview.htm?41/23/42363\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INJURY CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic injuries can range from minor to life-threatening. Several methods for measuring severity of injury exist. In order to appropriately triage the management of the trauma patient, one useful method to categorize injuries uses the following parameters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Injury extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trauma is defined by apparent injury to two or more body areas. Localized trauma involves only one anatomic region (eg, head and neck, chest and back, abdomen, extremities) of the body. Sometimes the extent of injury may be obvious; at other times this may not be readily apparent, and the clinical picture may evolve over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Injury type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The expected injuries differ based on whether they occur as a result of blunt trauma (eg, fall, motor vehicle collision) or penetrating trauma (eg, gunshot, stabbing, shrapnel from explosion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Injury severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of injury and physical examination findings are useful in the determination of severity. Assessment of severity will dictate the initial management and disposition of the injured child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/1\">",
"     1",
"    </a>",
"    ]. High risk trauma mechanisms predict patients who are more likely to be unstable or become unstable and, along with vital signs and physical findings, are often used to guide prehospital transport decisions and to initiate evaluation by a trauma team in hospital trauma centers (",
"    <a class=\"graphic graphic_table graphicRef60424 \" href=\"mobipreview.htm?41/23/42363\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57153 \" href=\"mobipreview.htm?29/18/29996\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH TO BLUNT TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt injury accounts for approximately 90 percent of all pediatric trauma. When blunt force is applied to a child's small body, multisystem trauma occurs frequently. However, the majority of injuries are mild to moderate in severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the pediatric patient with a history of mild or moderate blunt trauma begins with the primary and secondary surveys (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65952 \" href=\"mobipreview.htm?13/13/13534\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/2\">",
"     2",
"    </a>",
"    ]. The stable pediatric trauma patient should have a normal primary survey with the possible exception of tachycardia caused by age-appropriate anxiety and crying or mild lethargy (Glasgow coma scale &ge;14) (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"mobipreview.htm?2/58/2989\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During the secondary survey, the emergency provider determines the injury extent (multiple trauma or isolated trauma), injury type (blunt or penetrating), and injury severity based on all physical findings.",
"   </p>",
"   <p>",
"    The primary and secondary surveys may be truncated in the setting of trivial trauma or obviously isolated trauma (eg, struck on the knee by a baseball, twisted ankle, or fall on an outstretched arm). All other children should undergo a complete physical examination to ensure that subtle findings of significant injury are not missed.",
"   </p>",
"   <p>",
"    Based on the initial brief history and physical assessment, injuries in each anatomic region in children with blunt trauma can be classified as mild (eg, isolated bruise), moderate (eg, head trauma with loss of consciousness), or severe (eg, liver laceration after blunt trauma) (",
"    <a class=\"graphic graphic_table graphicRef57153 \" href=\"mobipreview.htm?29/18/29996\">",
"     table 4",
"    </a>",
"    ). The severity of injuries may be estimated as a guide to management. This preliminary estimate is based on the amount of force and mechanism of injury, the physical examination findings, including the vital signs, and evidence of superficial versus internal injuries. Further diagnostic evaluation depends on the clinical assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Head trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children evaluated in the emergency department (ED) for blunt head trauma have sustained a minor injury and require no further intervention unless they have a predisposition to delayed intracranial bleeding (eg, bleeding dyscrasia). Some children may be hemodynamically stable after head trauma but may warrant neuroimaging. Potential indications include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=see_link&amp;anchor=H20#H20\">",
"     \"Minor head trauma in infants and children\", section on 'Indications for neuroimaging'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe mechanism of injury (eg, rollover motor vehicle crash)",
"     </li>",
"     <li>",
"      Loss of consciousness",
"     </li>",
"     <li>",
"      Lethargy or altered mental status",
"     </li>",
"     <li>",
"      A palpable skull fracture or signs of a basilar skull fracture",
"     </li>",
"     <li>",
"      Focal neurologic findings",
"     </li>",
"     <li>",
"      Severe headache",
"     </li>",
"     <li>",
"      The occurrence of findings that point towards increased intracranial pressure (eg, persistent vomiting)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient disposition in cases with indicators of injuries that are potentially more than minor severity is determined by CT findings and by the patient's clinical findings. Previously healthy patients who undergo CT scanning with normal results are generally discharged home.",
"   </p>",
"   <p>",
"    Some clinicians may choose to observe children with very brief (eg, a few seconds) or uncertain history of loss of consciousness rather than ordering a head CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neck trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild injury mechanisms (eg, 9-year-old seat-belted passenger in a low speed motor vehicle collision [MVC]) with normal physical examination findings will only require conservative ED management, unless the patient has a predisposition to cervical spine injury (eg, Down syndrome, Klippel Feil syndrome, Morquio syndrome, Larsen syndrome) or an underlying illness (eg, hemophilia) that may result in delayed complications.",
"   </p>",
"   <p>",
"    Patients who are alert with no distracting injuries and no cervical spine symptoms or signs may be cleared clinically (",
"    <a class=\"graphic graphic_algorithm graphicRef70732 \" href=\"mobipreview.htm?12/52/13134\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/3\">",
"     3",
"    </a>",
"    ]. Otherwise, evaluation and treatment for cervical spine injury should commence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thoracic trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of minimal trauma to the chest (eg, a 6-year-old punched by a classmate) with normal vital signs, breathing, and only superficial chest",
"    <span class=\"nowrap\">",
"     wall/skin",
"    </span>",
"    injuries is unlikely to require radiologic imaging, and the patient may be discharged home.",
"   </p>",
"   <p>",
"    The presence of abnormal vital signs (including oxygen saturation), a history of moderate thoracic trauma as defined by the amount of force involved (eg, a 15-year-old struck by a \"fastball\"), significant bony tenderness, or abnormal breath or cardiac sounds suggest potential intrathoracic injury. Patients with these findings warrant additional evaluation for potential life-threatening thoracic injury (eg, pulmonary contusion, cardiac contusion, pneumothorax). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12807?source=see_link\">",
"     \"Chest wall injuries in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3495?source=see_link\">",
"     \"Intrathoracic injuries in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike penetrating trauma, which usually results in wounds that are apparent upon inspection, injuries caused by blunt abdominal trauma must be suspected from historical information, particularly the mechanism of injury, and careful physical examination. Mechanisms of trauma that are associated with intraabdominal injury include MVC, seat belt usage, and falls from a height greater than 20 feet (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, serious intraabdominal injury, especially splenic laceration or hematoma can occur with seemingly trivial abdominal trauma to the left upper quadrant. For this reason, even abdominal trauma sustained as a result of minimal force (eg, a 2-year-old struck by a ball) requires a thorough physical examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe multiple trauma, regardless of the presence of tenderness on abdominal examination, typically undergo abdominal CT with IV contrast if immediate operative management is not required (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A clinical decision rule for the identification of children with intra-abdominal injuries after blunt trauma has identified the following &ldquo;high-risk&rdquo; variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low age-adjusted systolic blood pressure",
"     </li>",
"     <li>",
"      Abdominal tenderness",
"     </li>",
"     <li>",
"      Femur fracture",
"     </li>",
"     <li>",
"      Increased liver enzyme levels (aspartate aminotransferase &gt;200",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      or alanine aminotransferase &gt;125",
"      <span class=\"nowrap\">",
"       U/L)",
"      </span>",
"     </li>",
"     <li>",
"      Microscopic hematuria (urinalysis &gt;5",
"      <span class=\"nowrap\">",
"       RBC/high",
"      </span>",
"      powered field)",
"     </li>",
"     <li>",
"      Initial hematocrit level less than 30 perfect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of these variables would indicate that the child was not at low risk for intra-abdominal injury. If none of these variables are present, the child could be considered to be at low risk for intra-abdominal injury and many not require an abdominal CT for evaluation. Clinical observation could be a management strategy for such patients.",
"   </p>",
"   <p>",
"    Potential indications for abdominal CT in children sustaining blunt abdominal trauma are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Abdominal CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     With tenderness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal or costovertebral angle tenderness suggests potential intraabdominal injury and warrants further diagnostic evaluation and monitoring for internal hemorrhage. Hematocrit or hemoglobin, liver enzymes (aspartate aminotransferase transferase [AST], alanine aminotransferase [ALT]), rapid urine dipstick for blood, and serial examinations of the abdomen may identify those patients who deserve additional radiological evaluation with abdominal CT with IV contrast. Patients with normal laboratory studies and resolving abdominal tenderness without vomiting may be discharged home. Patients with persistent pain or laboratory abnormalities warrant an abdominal CT with IV contrast.",
"   </p>",
"   <p>",
"    For patients who warrant abdominal CT based upon clinical findings alone (eg, low age-adjusted blood pressure, significant abdominal tenderness, femur fracture in the setting of multiple trauma), AST and ALT typically does not add additional information regarding the presence of liver injury and can be omitted from the initial evaluation. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Abdominal trauma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Abdominal CT is the preferred imaging modality for the evaluation of blunt abdominal trauma in hemodynamically stable children. CT is sensitive and specific in diagnosing liver, spleen, and retroperitoneal injuries. CT is less sensitive in detecting injuries of the pancreas, intestinal tract, bladder, and lumbar spine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Moderate blunt abdominal trauma (eg, 10-year-old restrained passenger with a seat belt contusion after a MVC) usually requires evaluation with complete blood count, AST, ALT, lipase, and abdominal CT. In addition, intravenous (IV) access and fluid resuscitation should occur. Elevated liver enzyme values (AST &gt;200",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    [3.33",
"    <span class=\"nowrap\">",
"     microkat/L]",
"    </span>",
"    or ALT &gt;125",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    [2.08",
"    <span class=\"nowrap\">",
"     microkat/L])",
"    </span>",
"    are highly associated with intraabdominal injury following blunt trauma in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/4\">",
"     4",
"    </a>",
"    ]. Hospitalization is often necessary for the patient with moderate to severe intraabdominal trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Transaminases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Without tenderness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without abdominal tenderness but with significant mechanism may undergo urine evaluation for red blood cells, especially if kidney trauma is suspected. The most common screening test for hematuria is the urinary dipstick test for blood. A positive dipstick for hematuria is confirmed by a microscopic examination of the sediment of 10 to 15 mL of centrifuged fresh urine.",
"   </p>",
"   <p>",
"    The microscopic examination is the gold standard for the detection of hematuria. Dipsticks for hemoglobin are as sensitive as the urine sediment examination, but result in more false-positive tests. In comparison, false-negative dipstick tests are unusual; as a result, a negative dipstick reliably excludes abnormal hematuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gross hematuria is highly suggestive of serious renal injury and warrants further radiologic investigation. In addition, urinalysis demonstrating &gt;20 red blood cells per high-powered field also suggests intraabdominal injury after blunt trauma in children. This finding warrants serial examinations, evaluation of AST and ALT, and abdominal CT if the patient develops tenderness or has elevated liver enzyme studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extremity trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild injuries to the extremities (eg, a 12-year-old trips and falls and now has pain of the wrist) often require radiographic examination for possible fracture, especially involving the growth plate. A normal radiograph does not exclude a Salter-Harris type I fracture of the growth plate, which may be diagnosed based on focal tenderness at the physis (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obvious dislocations and fractures with neurovascular compromise should be reduced and immobilized as expeditiously as possible. Dislocations of the large joints (knee, hip, and elbow) may lead to vascular compromise if not reduced. Patients with crush injuries should be carefully evaluated for compartment syndrome, which may manifest as pain, paresthesias, pallor, and in some cases decreased or absent pulses 6 to 24 hours after the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Open fractures create a communication between the external environment and the bone. These injuries have significant infectious risk and are often complicated by delayed wound healing. They require urgent orthopedic consultation. Additionally, prophylactic antibiotics should be administered as soon as possible (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, maximum: 2 grams; or in children allergic to penicillin or cephalosporins,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, maximum: 1.8 grams) and tetanus prophylaxis given (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     APPROACH TO PENETRATING TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to penetrating trauma is similar to blunt trauma, although significant injury is more likely. The emergency provider should have a low threshold for obtaining surgical consultation, especially in patients injured by gunshot wounds to the head, neck, thorax, or abdomen. The site of injury, velocity of the missile, and its distance from the patient are important factors in determining the extent and severity of injury (",
"    <a class=\"graphic graphic_table graphicRef57153 \" href=\"mobipreview.htm?29/18/29996\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating trauma is less frequent in children than blunt trauma but accounts for more than 10 percent of admissions to most major pediatric trauma centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/8\">",
"     8",
"    </a>",
"    ]. Gunshot wounds and stab wounds are the more common causes of penetrating trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/9\">",
"     9",
"    </a>",
"    ]. Homicide and suicide from firearms are leading causes of death for children 0 to 19 years old in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gunshot wounds are further divided into high and low velocity injuries. Bone penetration requires a velocity of approximately 350 feet per second (107 meters per second). Because low velocity weapons (eg, .22-caliber guns, other handguns, air guns) do not typically penetrate bone, they tend to produce a more erratic path through soft tissue, following tissue planes.",
"   </p>",
"   <p>",
"    Medium and high velocity weapons (such as AK 47s) also cause injury by opening and closing tissue with force. This action creates a wave of energy that can damage intraperitoneal structures, despite entirely extraperitoneal tracking of the missile (blast effect). Clinicians may underestimate tissue damage from this effect. Military weapons and hunting rifles can fire at speeds over 2000 to 3000 feet per second (610 to 910 meters per second). Thus, they produce wounds with a more direct, predictable course through bone and soft tissue.",
"   </p>",
"   <p>",
"    Shot gun wounds (SGW) have different characteristic patterns of injury given their use of pellets, rather than single bullets, and longer barrels. Typically initial pellet velocity decreases quickly and spread increases with distance from the target. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3943?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\", section on 'Mechanisms of injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Head trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating wounds clearly limited to the scalp (eg, BB gun wound) may be repaired primarily in the ED. If there is any concern for penetration into the cranial vault (eg, moderate to high velocity gunshot wound to the head, dog bite), CT evaluation for skull fracture and neurosurgical consultation should occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/8\">",
"     8",
"    </a>",
"    ]. Any protruding object should be left in place until definitive management can be performed by a neurosurgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neck trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with injuries penetrating the platysma require stabilization and emergent surgical consultation. Penetrating neck injury may cause vascular injury with significant hemorrhage, damage to the spinal cord, larynx, or trachea. Disruption of the larynx or trachea may result in displacement and obstruction of the airway or bleeding into the tracheobronchial tree. Any signs of airway compromise or suspicion of platysma penetration warrants endotracheal intubation (",
"    <a class=\"graphic graphic_algorithm graphicRef51111 \" href=\"mobipreview.htm?11/21/11615\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=see_link&amp;anchor=H11#H11\">",
"     \"Penetrating neck injuries\", section on 'Emergency management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical consultation for neck exploration is recommended for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continued bleeding from the wound or shock",
"     </li>",
"     <li>",
"      Blood in the aerodigestive tract",
"     </li>",
"     <li>",
"      Subcutaneous emphysema",
"     </li>",
"     <li>",
"      Hoarseness",
"     </li>",
"     <li>",
"      Stridor",
"     </li>",
"     <li>",
"      Aphonia",
"     </li>",
"     <li>",
"      Neurologic deficits",
"     </li>",
"     <li>",
"      Inability to observe or study the child prior to operation for other injuries",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asymptomatic patients may be evaluated with diagnostic testing and if negative may be observed, without mandatory surgical exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/8,9,11,12\">",
"     8,9,11,12",
"    </a>",
"    ]. Wounds superficial to the platysma muscle may be repaired in the ED. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=see_link&amp;anchor=H14#H14\">",
"     \"Penetrating neck injuries\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thoracic trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gunshot wounds and stab wounds are the major causes of penetrating thoracic trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/13\">",
"     13",
"    </a>",
"    ]. A child with a penetrating wound to the thorax is at high risk for major traumatic injury, including pneumothorax, hemothorax, cardiac tamponade, open pneumothorax,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exsanguinating hemorrhage and requires emergent surgical consultation. Initial management consists of a thoracostomy tube and fluid resuscitation, but early surgical intervention may be necessary, especially with gunshot wounds. In addition, a FAST exam may help identify cardiac injuries with associated hemopericardium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Abdominal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gunshot wounds frequently lead to significant intraperitoneal injury and often require laparotomy for evaluation and management. Thus, emergent surgical consultation is warranted for these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16904?source=see_link&amp;anchor=H6#H6\">",
"     \"Penetrating trauma of the upper and lower genitourinary tract\", section on 'Primary evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stab wounds may be superficial or deep to the peritoneum. Superficial wounds may be explored and repaired in the ED if penetration of the peritoneum can be excluded clinically with a high degree of certainty. Deeper wounds through the peritoneum require surgical consultation and may necessitate a laparotomy. Any protruding foreign body should be left in place until definitive management can be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Spine trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In penetrating trauma caused by gunshot wounds, the direct path and the concussive effects of the missile can lead to injury of the spinal cord and spine. Helical CT of the involved area of the spine is recommended to determine the missile trajectory, extent of bony involvement, stability of the injury, and the presence of a spinal epidural hematoma. Patients with evidence of spinal injury should be immobilized and emergent surgical consultation obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Extremity trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild penetrating trauma should receive appropriate wound care and tetanus prophylaxis, if indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"     table 7",
"    </a>",
"    ). Radiographs should be obtained when the presence of any radio-opaque foreign body (eg, glass) is suspected. Moderate trauma requires a careful examination with local exploration to determine the extent of injury after external hemorrhage is controlled.",
"   </p>",
"   <p>",
"    Patients with enlarging hematoma, pulsatile bleeding wound, bruit or thrill noted distal to injury, or signs of distal ischemia (pain, pallor, pulselessness, paresthesias, or paralysis) warrant operative exploration for likely arterial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stable patients with suspected extremity vascular injury should undergo diagnostic studies as determined by the managing surgical team [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40119/abstract/14\">",
"     14",
"    </a>",
"    ]. Duplex ultrasound, Doppler ultrasound flow studies, CT angiography, and arteriography constitute the possible radiographic methods of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DEFINITIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After physical examination, most stable pediatric trauma patients are able to go home, including those who have sustained penetrating trauma. Patients that warrant additional studies and possible admission include patients with abdominal tenderness or hematuria after blunt trauma or those with significant penetrating injury. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Abdominal trauma'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Approach to penetrating trauma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stable pediatric trauma patient refers to an injured child who initially has normal or near normal vital signs, vital functions (airway, breathing, circulation, mental status), and no readily apparent critical injury (",
"      <a class=\"graphic graphic_table graphicRef60424 \" href=\"mobipreview.htm?41/23/42363\">",
"       table 2",
"      </a>",
"      ). It is imperative for the trauma provider to use normative values for children as opposed to adults when assessing vital signs (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"mobipreview.htm?27/37/28252\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"       calculator 2",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3477?source=see_link\">",
"       \"Trauma management: Unique pediatric considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In any child with a history of trauma, determination of the extent (multiple or single), nature (blunt or penetrating), and severity (mild, moderate, or severe) is important in the assessment and management of the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Injury classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stable pediatric trauma patient should have a normal primary survey with the possible exception of tachycardia caused by age-appropriate anxiety and crying or mild lethargy (Glasgow coma scale &gt;13) (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"mobipreview.htm?2/58/2989\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      During the secondary survey, the emergency provider determines the injury extent (multiple trauma or isolated trauma), injury type (blunt or penetrating), and injury severity based on all physical findings (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65952 \" href=\"mobipreview.htm?13/13/13534\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to blunt trauma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Approach to penetrating trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the initial brief history and physical assessment, injuries in each anatomic region in children with blunt trauma can be classified as mild, moderate, and severe (",
"      <a class=\"graphic graphic_table graphicRef57153 \" href=\"mobipreview.htm?29/18/29996\">",
"       table 4",
"      </a>",
"      ). This estimate of severity guides further management. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Approach to blunt trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to penetrating trauma is similar to blunt trauma although severe trauma is more likely. The site of injury, velocity of the missile, and its distance from the patient are important factors in determining the extent of injury. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Approach to penetrating trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After physical examination, most stable pediatric trauma patients are able to go home, including those who have sustained penetrating trauma. Patients that warrant additional studies and possible admission include patients with abdominal tenderness or hematuria after blunt trauma or those with significant penetrating injury. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Abdominal trauma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Approach to penetrating trauma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ruddy, RM, Fleisher, GR. An Approach to the Injured Child. In: Textbook of Pediatric Medicine , 5th, Fleisher, GR, Ludwig, S, Henretiq, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1339.",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors. American College of Surgeons, Chicago 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/3\">",
"      Slack SE, Clancy MJ. Clearing the cervical spine of paediatric trauma patients. Emerg Med J 2004; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/4\">",
"      Holmes JF, Mao A, Awasthi S, et al. Validation of a prediction rule for the identification of children with intra-abdominal injuries after blunt torso trauma. Ann Emerg Med 2009; 54:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/5\">",
"      Holmes JF, Sokolove PE, Brant WE, et al. Identification of children with intra-abdominal injuries after blunt trauma. Ann Emerg Med 2002; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     Bachman, D, Santora, S. Orthopedic Trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretiq, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1525.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/7\">",
"      Stewart DG Jr, Kay RM, Skaggs DL. Open fractures in children. Principles of evaluation and management. J Bone Joint Surg Am 2005; 87:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/8\">",
"      Cotton BA, Nance ML. Penetrating trauma in children. Semin Pediatr Surg 2004; 13:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/9\">",
"      Abujamra L, Joseph MM. Penetrating neck injuries in children: a retrospective review. Pediatr Emerg Care 2003; 19:308.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ncipc/wisgars (Accessed on March 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/11\">",
"      Mutabagani KH, Beaver BL, Cooney DR, Besner GE. Penetrating neck trauma in children: a reappraisal. J Pediatr Surg 1995; 30:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/12\">",
"      Kim MK, Buckman R, Szeremeta W. Penetrating neck trauma in children: an urban hospital's experience. Otolaryngol Head Neck Surg 2000; 123:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/13\">",
"      Cooper A, Barlow B, DiScala C, String D. Mortality and truncal injury: the pediatric perspective. J Pediatr Surg 1994; 29:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40119/abstract/14\">",
"      Newton EJ, Love J. Acute complications of extremity trauma. Emerg Med Clin North Am 2007; 25:751.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6572 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40119=[""].join("\n");
var outline_f39_11_40119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INJURY CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Injury extent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Injury type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Injury severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH TO BLUNT TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Head trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neck trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - With tenderness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Without tenderness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extremity trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      APPROACH TO PENETRATING TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Head trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neck trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Abdominal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Spine trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Extremity trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DEFINITIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6572|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/52/13134\" title=\"algorithm 1\">",
"      Cervical spine clinical clearance algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/21/11615\" title=\"algorithm 2\">",
"      Penetrating neck injury through platysma algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6572|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 2\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/37/28252\" title=\"table 1\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/23/42363\" title=\"table 2\">",
"      Critical physical findings of trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/42/684\" title=\"table 3\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/18/29996\" title=\"table 4\">",
"      Injury severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/13/13534\" title=\"table 5\">",
"      Trauma secondary survey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/58/2989\" title=\"table 6\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 7\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12807?source=related_link\">",
"      Chest wall injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3495?source=related_link\">",
"      Intrathoracic injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2026?source=related_link\">",
"      Penetrating neck injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16904?source=related_link\">",
"      Penetrating trauma of the upper and lower genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3477?source=related_link\">",
"      Trauma management: Unique pediatric considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40120="Celecoxib: Drug information";
var content_f39_11_40120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Celecoxib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40949?source=see_link\">",
"    see \"Celecoxib: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/54/5992?source=see_link\">",
"    see \"Celecoxib: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeleBREX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celebrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"     Oral: 200 mg/day as a single dose or in divided doses twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ankylosing spondylitis:",
"     </b>",
"     Oral: 200 mg/day as a single dose or in divided doses twice daily; if no effect after 6 weeks, may increase to 400 mg/day. If no response following 6 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling; Recommended maximum dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: 100-200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pain or primary dysmenorrhea:",
"     </b>",
"     Oral: Initial dose: 400 mg, followed by an additional 200 mg if needed on day 1; maintenance dose: 200 mg twice daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling; Recommended maximum dose for treatment of acute pain: 400 mg/day up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in poor CYP2C9 metabolizers (eg, CYP2C9*3/*3):",
"     </b>",
"     Consider reducing initial dose by 50%; consider alternative treatment in patients with JIA who are poor CYP2C9 metabolizers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: Recommended maximum dose: 100 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4028614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/54/5992?source=see_link\">",
"      see \"Celecoxib: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Oral: Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;10 kg to &le;25 kg: 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;25 kg: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosing adjustment in poor CYP2C9 metabolizers (eg, CYP2C9*3/*3):",
"     </i>",
"     Consider  alternative.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific adjustment based on age is recommended. However, the AUC in elderly patients may be increased by 50% as compared to younger subjects. Initiate at the lowest recommended dose in patients weighing &lt;50 kg.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Advanced renal disease: Use is not recommended; however, if celecoxib treatment cannot be avoided, monitor renal function closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe renal insufficiency: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Abnormal renal function tests (persistent or worsening): Discontinue use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F148412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate hepatic impairment (Child-Pugh class B): Reduce dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Abnormal liver function tests (persistent or worsening): Discontinue use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeleBREX&reg;: 50 mg, 100 mg, 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088567.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088567.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4028615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Capsules may be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce. The contents of the capsules sprinkled onto applesauce may be stored under refrigeration for up to 6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the signs and symptoms of osteoarthritis, ankylosing spondylitis, juvenile idiopathic arthritis (JIA), and rheumatoid arthritis; management of acute pain; treatment of primary dysmenorrhea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CeleBREX&reg; may be confused with CeleXA&reg;, Cerebyx&reg;, Cervarix&reg;, Clarinex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     0.1% to 1.9%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, aortic valve incompetence, chest pain, coronary artery disorder, edema, facial edema,  hypertension (aggravated), MI, palpitation, sinus bradycardia, tachycardia, ventricular hypertrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, fatigue,  hypoesthesia, migraine, nervousness,  pain, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, cellulitis, dermatitis, dry skin, photosensitivity, pruritus, rash (erythematous), rash (maculopapular), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, hypercholesterolemia, hyperglycemia, hypokalemia, ovarian cyst, testosterone decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, constipation, diverticulitis, dysphagia, eructation, esophagitis, gastritis, gastroenteritis, gastroesophageal reflux, gastrointestinal ulcer, hemorrhoids, hiatal hernia, melena, stomatitis, tenesmus, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis, dysuria, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, thrombocythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthrosis, CPK increased, hypertonia, leg cramps, myalgia, paresthesia, synovitis, tendonitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctival hemorrhage, vitreous floaters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Deafness, labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, BUN increased, creatinine increased, hematuria, nonprotein nitrogen increased, renal calculi",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, bronchospasm, dyspnea, epistaxis, laryngitis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, allergy aggravated, cyst, diaphoresis, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;0.1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, anaphylactoid reactions, angioedema, anosmia, aplastic anemia, aseptic meningitis, cerebrovascular accident, CHF, cholelithiasis, colitis, DVT, erythema multiforme, esophageal perforation, exfoliative dermatitis, gangrene, gastrointestinal bleeding, hepatic failure, hepatic necrosis, hepatitis (including fulminant), hypoglycemia, hyponatremia, ileus, interstitial nephritis, intestinal obstruction, intestinal perforation, intracranial hemorrhage, jaundice, leukopenia, pancreatitis, pancytopenia, pulmonary embolism, renal papillary necrosis, sepsis, Stevens-Johnson syndrome, sudden death, suicide, syncope, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, vasculitis, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Pregnancy (third trimester); women who are breast-feeding; severe, uncontrolled heart failure; active gastrointestinal ulcer (gastric, duodenal, peptic) or bleeding; inflammatory bowel disease; cerebrovascular bleeding; severe liver impairment or active hepatic disease; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; use in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure, anaphylactic reactions and angioedema may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. New onset hypertension or exacerbation of hypertension may occur (NSAIDS may impair response to thiazide or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention, use with caution in patients with edema or heart failure. Long-term cardiovascular risk in children has not been evaluated. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of serious gastrointestinal ulceration, bleeding, and perforation (may be fatal).",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Anemia may occur; monitor hemoglobin or hematocrit in patients on long-term treatment. Celecoxib does not usually affect PT, PTT or platelet counts; does not inhibit platelet aggregation at approved doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning and in patients without prior known sulfa allergy; discontinue use at first sign of rash (or any other hypersensitivity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe and potentially fatal bronchospasm may occur. Use with caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Celecoxib is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft surgery (CABG).",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroid-dependent diseases: Should not be considered a treatment or replacement of corticosteroid-dependent diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cytochrome P450 isoenzyme 2C9 deficiency: Use with caution in patients with known or suspected deficiency of cytochrome P450 isoenzyme 2C9; poor metabolizers may have higher plasma levels due to reduced metabolism; consider reduced initial doses. Alternate therapies should be considered in patients with JIA who are poor metabolizers of CYP2C9.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate hepatic impairment; dosage adjustment recommended. Not recommended for patients with severe hepatic impairment. Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, jaundice, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, if systemic manifestations occur, or with persistent or worsening abnormal hepatic function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function. Dose-dependent decreases in prostaglandin synthesis may result from NSAID use, causing a reduction in renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, ACE inhibitors, angiotensin II receptor blockers, and the elderly are at greater risk for renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease or severe renal insufficiency; discontinue use with persistent or worsening abnormal renal function tests. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: When used for juvenile idiopathic arthritis (JIA), celecoxib is not FDA-approved in children &lt;2 years of age or in children &lt;10 kg. Use caution with systemic-onset JIA (may be at risk for disseminated intravascular coagulation). Safety and efficacy have not been established for use in children for indications other than JIA.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F148430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor). Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: NSAID (COX-2 Inhibitor) may enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (COX-2 Inhibitor) may enhance the anticoagulant effect of Vitamin K Antagonists. NSAID (COX-2 Inhibitor) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F148400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (increased GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Peak concentrations are delayed and AUC is increased by 10% to 20% when taken with a high-fat meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid concomitant use with herbs possessing anticoagulation/antiplatelet properties, including alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnuts, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (prior to 30 weeks gestation)/D (&ge;30 weeks gestation) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F148389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal studies; therefore, celecoxib is classified as pregnancy category C. Celecoxib is a NSAID that primarily inhibits COX-2 whereas other currently available NSAIDs are nonselective for COX-1 and COX-2. The effects of this selective inhibition to the fetus have not been well studied and limited information is available specific to celecoxib. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because it may cause premature closure of the ductus arteriosus, the use of celecoxib is not recommended &ge;30 weeks gestation. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including celecoxib. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F148414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F148390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of celecoxib are found in breast milk. The manufacturer recommends that caution be exercised when administering celecoxib to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F148391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F148388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CeleBREX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $107.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $382.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $627.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $565.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC; blood chemistry profile; occult blood loss and periodic liver function tests; monitor renal function (urine output, serum BUN and creatinine; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; blood pressure (baseline and during treatment); observe for weight gain, edema; observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     JIA: Monitor for development of abnormal coagulation tests with systemic onset JIA",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aubrex (PH);",
"     </li>",
"     <li>",
"      Celbexx (PK);",
"     </li>",
"     <li>",
"      Celcox (IL);",
"     </li>",
"     <li>",
"      Celcoxx (PH);",
"     </li>",
"     <li>",
"      Celebra (BR, CN, CR, DK, DO, FI, GT, HN, IL, NI, NO, PA, SE, SV, UY);",
"     </li>",
"     <li>",
"      Celebrex (AE, AR, AT, AU, BD, BE, BF, BG, BH, BJ, CH, CI, CL, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HK, ID, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Celecox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Celexib (PH);",
"     </li>",
"     <li>",
"      Celib (IN);",
"     </li>",
"     <li>",
"      Cox-2 (PH);",
"     </li>",
"     <li>",
"      Coxel (AR);",
"     </li>",
"     <li>",
"      Coxoral (PH);",
"     </li>",
"     <li>",
"      Coxzan (PH);",
"     </li>",
"     <li>",
"      Dolocox (EC);",
"     </li>",
"     <li>",
"      Eliflam (PY);",
"     </li>",
"     <li>",
"      Flamar (PH);",
"     </li>",
"     <li>",
"      Flaxel (PE);",
"     </li>",
"     <li>",
"      Lexfin (CO);",
"     </li>",
"     <li>",
"      Lincox (PH);",
"     </li>",
"     <li>",
"      Miodar (CO);",
"     </li>",
"     <li>",
"      Onsenal (AT, DE, DK, ES, IE, TR);",
"     </li>",
"     <li>",
"      Swelcid (PH);",
"     </li>",
"     <li>",
"      Valdyne (CR, DO, GT, HN, NI, NZ, PA, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase-2 (COX-2), which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties. Celecoxib does not inhibit cyclooxygenase-1 (COX-1) at therapeutic concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): ~400 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~97% primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9; forms inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: Unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~11 hours (fasted)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~57% as metabolites, &lt;3% as unchanged drug); urine (27% as metabolites, &lt;3% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geis GS, et al, &ldquo;Efficacy and Safety of Celecoxib, A Specific COX-2 Inhibitor, in Patients With Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41(9 Suppl):316:1699.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karim A, et al, &ldquo;Celecoxib, a Specific COX-2 Inhibitor, Lacks Significant Drug-Drug Interactions With Methotrexate or Warfarin,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41(9 Suppl):315:1698.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/9485090/pubmed\" id=\"9485090\" target=\"_blank\">",
"        9485090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane NE, &ldquo;Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1997, 24(Suppl 49):20-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/9002006/pubmed\" id=\"9002006\" target=\"_blank\">",
"        9002006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky PE and Isakson PC, &ldquo;Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1997, 24(Suppl 49):9-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/9002004/pubmed\" id=\"9002004\" target=\"_blank\">",
"        9002004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mengle-Gaw L, et al, &ldquo;A Study of the Platelet Effects of SC-58635, A Novel COX-2 Selective Inhibitor,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41(9 Suppl):93-374.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Needleman P and Isakson PC, &ldquo;The Discovery and Function of COX-2,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 1997, 24(Suppl 49):6-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/9002003/pubmed\" id=\"9002003\" target=\"_blank\">",
"        9002003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nussmeier NA, Whelton AA, Brown MT, et al, &ldquo;Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib After Cardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1081-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/15713945/pubmed\" id=\"15713945\" target=\"_blank\">",
"        15713945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon LS, et al, &ldquo;Preliminary Study of the Safety and Efficacy of SC-58635, a Novel Cyclo-oxygenase 2 Inhibitor: Efficacy and Safety in Two Placebo-Controlled Trials in Osteoarthritis and Rheumatoid Arthritis, and Studies of Gastrointestinal and Platelet Effects,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1998, 41:1591-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/9751091/pubmed\" id=\"9751091\" target=\"_blank\">",
"        9751091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomon SD, McMurray JJ, Pfeffer MA, et al, &ldquo;Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1071-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/11/40120/abstract-text/15713944/pubmed\" id=\"15713944\" target=\"_blank\">",
"        15713944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8847 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40120=[""].join("\n");
var outline_f39_11_40120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708651\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148404\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148405\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148436\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148409\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028614\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148410\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148411\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148412\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148366\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874407\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028615\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148382\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148446\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148434\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148386\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148370\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148430\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148400\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148377\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148389\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148414\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148390\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148391\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148388\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148379\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148392\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148369\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148385\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40949?source=related_link\">",
"      Celecoxib: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/54/5992?source=related_link\">",
"      Celecoxib: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40121="Diseases potentially acquired by travel to sub-Saharan Africa";
var content_f39_11_40121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases potentially acquired by travel to sub-Saharan Africa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     David Murdoch, MD, MSc, DTM&amp;H, FRACP, FRCPA, FFSc(RCPA)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40121/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/11/40121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sub-Saharan Africa refers to the central region of the African continent between the Sahara Desert in the North to a latitude of about 20&ordm;S (",
"    <a class=\"graphic graphic_figure graphicRef68381 \" href=\"mobipreview.htm?21/52/22342\">",
"     figure 1",
"    </a>",
"    ). It encompasses tropical rain forests in the West and center, desert areas in the North, and wooded steppes in the East.",
"   </p>",
"   <p>",
"    For the purposes of this discussion, the countries within Sub-Saharan Africa are Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Cote d'Ivoire, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Niger, Nigeria, R&eacute;union, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Tanzania, Togo, Uganda, Democratic Republic of Congo (Zaire), Zambia, and Zimbabwe. The remaining countries of southern Africa include Botswana, Lesotho, Namibia, St. Helena, South Africa, and Swaziland.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURVEILLANCE DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest contemporary experience in travel-related disease in developing countries comes from GeoSentinel, which is the global surveillance network of the International Society of Travel Medicine and the United States Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 report from 30 GeoSentinel sites in developed countries provided clinical-based surveillance information on 17,353 ill travelers who had returned from developing countries and were seen between June 1996 and August 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/1\">",
"     1",
"    </a>",
"    ]. It was estimated that up to 8 percent of travelers to developing countries are ill enough to seek health care while abroad or after returning home.",
"   </p>",
"   <p>",
"    The following observations were noted in the 4524 ill travelers who had returned from sub-Saharan Africa:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients (70 percent) presented within one month after returning from travel, and 18 percent required hospitalization.",
"     </li>",
"     <li>",
"      The primary manifestations in about 65 percent of returned travelers fell into four major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, and nondiarrheal gastrointestinal disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with a systemic febrile illness, 62 percent had malaria, 1 percent had dengue, 6 percent had a rickettsial infection, and no cause was reported in 28 percent.",
"     </li>",
"     <li>",
"      Among patients with acute diarrhea, 35 percent had parasitic infection (mostly giardiasis and amebiasis), 25 percent had bacterial infection (mostly Campylobacter and, less often Shigella and nontyphoidal Salmonella), a small number had viral infection, and 40 percent had unspecified acute diarrhea.",
"     </li>",
"     <li>",
"      Among patients with dermatologic disorders, the most common were an insect bite, with or without superinfection, skin abscess, an allergic rash or reaction, and cutaneous larva migrans.",
"     </li>",
"     <li>",
"      Among patients with a nondiarrheal gastrointestinal disorder, 59 percent had intestinal nematode infection (mostly Strongyloides and Ascaris), 16 percent had gastritis or peptic ulcer disease, 15 percent had acute hepatitis, and 10 percent had hemorrhoids or constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later report from GeoSentinel specifically evaluated fever, which was the chief reason for seeking care in 28 percent of almost 25,000 ill returned travelers who were seen between 1997 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among ill travelers who had returned from sub-Saharan Africa, fever was present in 41 percent with the following distribution of causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      49 percent had a systemic febrile illness, mostly due to malaria (42 percent)",
"     </li>",
"     <li>",
"      10 percent had a diarrheal illness",
"     </li>",
"     <li>",
"      10 percent had a respiratory illness",
"     </li>",
"     <li>",
"      19 percent had an undiagnosed febrile illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ARTHROPOD-BORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is a major risk for most travelers to sub-Saharan Africa. Endemic areas exist in all countries in this region except for the islands of R&eacute;union and Seychelles, and at altitudes over 2600 m. Except for Mauritius and Cape Verde, Plasmodium falciparum is the predominant cause of malaria and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistance is widespread. Within endemic areas, transmission occurs year-round. Country-specific risk areas are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef59126 \" href=\"mobipreview.htm?36/31/37373\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , or Malarone is the recommended prophylactic agent for most travelers to malarious areas, except for Mauritius and Cape Verde where",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    can be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Yellow fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever is endemic throughout most of sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef74437 \" href=\"mobipreview.htm?11/14/11496\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/3\">",
"     3",
"    </a>",
"    ]. Several species of mosquitoes are the reservoir of yellow fever virus and transmit infection to monkeys as well as humans. In Africa, the main mosquito vectors are Aedes aegypti and Aedes simpsoni (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    ). Three types of transmission cycle for yellow fever exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sylvatic (or jungle) yellow fever occurs among monkeys in tropical rain forests; sporadic cases occur in humans who enter the forest.",
"     </li>",
"     <li>",
"      Intermediate yellow fever occurs in semi-humid savannas where semi-domestic mosquitoes infect both humans and monkeys and cause small scale epidemics.",
"     </li>",
"     <li>",
"      Urban yellow fever occurs when migrants introduce the virus into areas of high human population density resulting in large epidemics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     Yellow fever vaccine",
"    </a>",
"    is required for entry into most countries in sub-Saharan Africa. In addition, many neighboring countries of endemic regions require yellow fever certificates for travelers coming from infected areas. Yellow fever vaccine is generally safe and very effective, but as a live virus vaccine may be contraindicated in patients with immunocompromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of dengue fever have occurred in East Africa. However, this disease is much less of a problem in Africa than in parts of Asia and the Americas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other viral hemorrhagic fevers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to yellow fever and dengue, several other viral hemorrhagic fevers have caused localized outbreaks in Africa. These include Lassa fever, Rift Valley fever, Crimean-Congo hemorrhagic fever, and Ebola hemorrhagic fever. Most are zoonoses and are transmitted to humans by bites of infected ticks or mosquitoes, or via aerosols from infected rodents. Ebola virus and Marburg virus are transmitted via contact with body fluids from infected humans or animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lassa fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lassa fever is restricted to West Africa and transmission to humans occurs through aerosol spread, either from rodents (multimammate rat) or through close contact with infected individuals. The incubation period is about ten days (range 6 to 21 days). A CDC Health Advisory described a 38 year-old man who had been in Liberia for five months and who died in a New Jersey hospital from probable Lassa fever in August 2004; this was the first reported case in the United States since 1989 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/4\">",
"     4",
"    </a>",
"    ]. Person-to-person transmission can occur via exposure via percutaneous injury to body fluids that are infectious (eg, blood, urine, vomitus), unprotected contact with potentially infectious material (eg, touching vomitus), and mucosal exposure from splashes of body fluids.",
"   </p>",
"   <p>",
"    Data on the role of postexposure prophylaxis (PEP) for Lassa fever with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are limited. In general, PEP is warranted exclusively in the setting of definitive high risk exposure; these include: skin penetration by contaminated sharp instrument, contamination of mucous membranes or broken skin with blood or body secretions, intubation or suction without use of appropriate protective equipment, or prolonged continuous contact in an enclosed space without use of appropriate personal protective equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/5\">",
"     5",
"    </a>",
"    ]. PEP consists of ribavirin 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally (loading dose; maximum 2.5 g), followed by 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally (maximum 1 g) administered three times a day for 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rift Valley fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rift Valley fever (RVF) is an acute, febrile disease caused by the Rift Valley fever virus, which belongs to the family of Bunyaviridae, genus Phlebovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/6\">",
"     6",
"    </a>",
"    ]. RVF has been reported in many savanna regions of sub-Saharan Africa, especially following heavy rainfall. Outbreaks of Rift Valley fever have also been documented in West Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/7\">",
"     7",
"    </a>",
"    ]. Transmission to humans occurs via bites from infected mosquitoes or more frequently through close contact with infected mammals.",
"   </p>",
"   <p>",
"    Outbreaks have occurred in Kenya and Somalia; the largest one occurred in Keya during the 1997-1998 season when approximately 89,000 people were infected and 473 died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/8\">",
"     8",
"    </a>",
"    ]. In the Kenyan outbreak, more than 404 cases were reported with 118 deaths from November 2006 to January 25, 2007, a case fatality rate of 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/6\">",
"     6",
"    </a>",
"    ]. The most frequently reported symptoms among the first 97 cases included fever, headache, bleeding, malaise, muscle pain, back pain, vomiting, and joint pain. The diagnosis of RVF is confirmed by the detection of viral RNA by polymerase chain reaction (PCR) or detection of IgM antibodies against RVF virus by enzyme-linked immunosorbent assay (ELISA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ebola virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ebola virus was first identified in Sudan and Zaire in 1976 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/9\">",
"     9",
"    </a>",
"    ]. The RNA viruses, Ebola virus and Marburg virus, form the family Filoviridae.",
"   </p>",
"   <p>",
"    An epidemic in the Bandundu region of Zaire in 1995 resulted in 245 deaths. Subsequent Ebola virus outbreaks occurred in Congo, Gabon, Sudan, and Uganda. Transmission occurs through direct contact with body fluid from infected individuals.",
"   </p>",
"   <p>",
"    It has been estimated that the mortality rates differ among Ebola viruses isolated from different regions; mortality rates of 70 to 90 percent were seen in association with Zaire Ebola virus infections but were lower with Sudan Ebola virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/10\">",
"     10",
"    </a>",
"    ]. Variations in outcome during an epidemic may result in part from genetically determined differences in innate immune responses to the viruses.",
"   </p>",
"   <p>",
"    Serologic studies suggest that mild or asymptomatic episodes occur, although they are uncommon. A population-based serosurvey of 979 residents in Gabon found a seroprevalence rate of 1.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/11\">",
"     11",
"    </a>",
"    ]. The natural reservoir for this infection may be bats; in a field study where more than 1000 small vertebrates were collected during Ebola outbreaks in human and great apes between 2001 and 2003, asymptomatic infection was identified in three species of fruit bats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/12\">",
"     12",
"    </a>",
"    ]. Human infection may be countered by educational programs, since local populations eat fruit bats where Ebola outbreaks have occurred.",
"   </p>",
"   <p>",
"    The diagnosis is established either through detection of IgG antibodies using ELISA assays or via identification of Ebola RNA by reverse-transcription polymerase chain reaction. Diagnosis can be hampered due to reluctance of patients to undergo blood testing; however, assays using other specimens, such as oral fluid, have not been perfected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ebola virus is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19721?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1624?source=see_link\">",
"     \"Diagnosis and treatment of Ebola and Marburg hemorrhagic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Marburg virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marburg hemorrhagic fever is a highly fatal disease caused by a RNA virus in the Filoviridae family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/14\">",
"     14",
"    </a>",
"    ]. Marburg virus infection is rare and limited to countries in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/15\">",
"     15",
"    </a>",
"    ]. The reservoir of infection is unknown.",
"   </p>",
"   <p>",
"    Marburg hemorrhagic fever was first identified in 1967 after an infectious disease physician in a university hospital in Marburg, Germany, saw patients with a severe febrile illness associated with hemorrhage and shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/16\">",
"     16",
"    </a>",
"    ]. All the patients worked for a pharmaceutical manufacturer where they had contact with African green monkeys. The virus that was isolated was unrelated to any other known family of viruses and had a unique branching morphology.",
"   </p>",
"   <p>",
"    Virus can be transmitted to humans through direct contact with body fluids (eg, blood, saliva, and urine) of an infected person or animal or through unsterile injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/16\">",
"     16",
"    </a>",
"    ]. Marburg virus appears to be easily transmissible since health care workers have also been infected. The virus can survive for as long as several days on contaminated surfaces. The incubation period is estimated to be five to 10 days.",
"   </p>",
"   <p>",
"    The World Health Organization confirmed Marburg virus as the causative agent of an outbreak of viral hemorrhagic fever in the Uige Province in northern Angola in March 2005. This is the first outbreak to occur in an urban setting. More than 270 cases have been identified with a case fatality rate of 92 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/17\">",
"     17",
"    </a>",
"    ]. Approximately 75 percent of the cases occurred in children less than five years of age. Some of these cases were acquired through improperly sterilized injection equipment in a pediatric ward and clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/16\">",
"     16",
"    </a>",
"    ]. Approximately 5 percent of cases also occur in healthcare workers who do not have ready access to gloves and gowns.",
"   </p>",
"   <p>",
"    Marburg virus infection presents acutely with fever, chills, headache, and myalgia. After about five days, symptoms progress to include nausea, vomiting, chest pain, sore throat, abdominal pain and diarrhea. A maculopapular rash may also occur. Over time, signs and symptoms become increasingly severe and can include jaundice, weight loss, and delirium. Patients die from septic shock with massive hemorrhage and multiorgan failure.",
"   </p>",
"   <p>",
"    A serosurvey of 121 household contacts suggests that mild or asymptomatic disease is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/18\">",
"     18",
"    </a>",
"    ]. Diagnosis of suspected Marburg infection is established on clinical and epidemiologic grounds and confirmed by polymerase chain reaction, antigen-capture enzyme-linked immunosorbent assay (ELISA), immunoglobulin M ELISA, or virus isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-exposure protection against Marburg virus infection was demonstrated in a rhesus macaque model using an attenuated recombinant vesicular stomatitis virus, which expresses surface glycoprotein of Marburg virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/19\">",
"     19",
"    </a>",
"    ]. Eight animals were given a high-dose inoculation of Marburg virus that was originally isolated from a human case in Kenya. All five animals that were immunized 20 minutes after the viral inoculation survived while the three control animals developed fulminant disease and died by day 12. Protective immune responses appeared to be mediated through the production of neutralizing antibodies; detectable cellular immune responses were absent in treated animals. These data suggest that this recombinant vaccine may be effective in prevention and early post-exposure prophylaxis.",
"   </p>",
"   <p>",
"    Traveler's advisories have been posted at",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel/other/marburghf/index.htm\">",
"     www.cdc.gov/travel/other/marburghf/index.htm",
"    </a>",
"    . All persons should avoid contact with body fluids from potentially infected persons. Health care workers should use contact and droplet precautions, in addition to wearing eye protection or a face shield. Additional information about the outbreak in Angola is available at",
"    <a class=\"external\" href=\"file://www.who.int/\">",
"     www.who.int",
"    </a>",
"    . The largest outbreak prior to this occurred in the Democratic Republic of Congo in 1998, resulting in 154 cases and 128 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Marburg virus is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19721?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1624?source=see_link\">",
"     \"Diagnosis and treatment of Ebola and Marburg hemorrhagic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Crimean-Congo hemorrhagic fever (CCHF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crimean-Congo hemorrhagic fever is a severe, potentially fatal disease in humans caused by CCHF virus. The disease has been documented in parts of Africa, Asia, eastern Europe, and the Middle East. Transmission to humans occurs through tick bites, contact with a patient with CCHF during the acute stage of infection, or contact with blood or tissue from infected livestock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical course of CCHF has four distinct phases: incubation, prehemorrhagic, hemorrhagic, and convalescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/21\">",
"     21",
"    </a>",
"    ]. The incubation period that follows a tick bite is usually short (three to seven days). The prehemorrhagic period is characterized by the sudden onset of fever, headache, myalgia, and dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/22\">",
"     22",
"    </a>",
"    ]. Additional symptoms of diarrhea, nausea, vomiting are also seen in some cases. After approximately three days, hemorrhagic manifestations, from petechiae, large hematomas, and frank bleeding (vaginal, gastrointestinal, nose, urinary and respiratory tracts) usually follow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/23\">",
"     23",
"    </a>",
"    ]. The convalescence period begins in survivors about 10 to 20 days after onset of illness.",
"   </p>",
"   <p>",
"    Viral isolation needs to be conducted in biosafety level four laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/21\">",
"     21",
"    </a>",
"    ]. IgM and IgG antibodies are detectable by ELISA and immunofluorescence assays from about seven days after the onset of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/24\">",
"     24",
"    </a>",
"    ]. Specific IgM antibodies decline to undetectable levels approximately four months after presentation.",
"   </p>",
"   <p>",
"    Treatment is mainly supportive.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    has been demonstrated to be effective in observational clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. Patients should be treated for 10 days (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as an initial loading dose, then 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours for four days, and then 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours for six days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case fatality rates range from 3 to 30 percent; disseminated intravascular coagulation and vascular dysregulation is commonly seen in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/22\">",
"     22",
"    </a>",
"    ]. Higher serum levels of proinflammatory cytokines IL-6 and tumor necrosis factor (TNF) were demonstrated in patients with fatal infection than in those who survived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of suspected or proven CCHF infection, careful adherence to contact and droplet precautions and safe burial practices are critical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/27\">",
"     27",
"    </a>",
"    ]. Environmental surfaces should be cleansed via chlorination with household bleach (2 to 5 percent hypochlorite). Post exposure prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    should be considered for high risk contacts of CCHF patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/22,25,28,29\">",
"     22,25,28,29",
"    </a>",
"    ]. In addition, personal tick preventive measures should be implemented. Slaughter of animals that may have acquired infection should be avoided given the possibility of asymptomatic viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     African trypanosomiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;African trypanosomiasis (sleeping sickness) is endemic throughout much of sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef63345 \" href=\"mobipreview.htm?34/57/35729\">",
"     figure 3",
"    </a>",
"    ). Countries with the highest endemicity include Angola, Cameroon, Central African Republic, Chad, Congo, Cote d'Ivoire, Democratic Republic of Congo, Guinea, Mozambique, Sudan, Tanzania, and Uganda. The prevalence of trypanosomiasis in many countries is increasing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=see_link\">",
"     \"Epidemiology, pathogenesis, and prevention of African trypanosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38681?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two different species of parasite cause two epidemiologically distinct diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      West African trypanosomiasis is caused by Trypanosoma brucei gambiense, humans are the primary reservoir, it occurs mainly in wooded areas along rivers, and tourists are rarely infected.",
"     </li>",
"     <li>",
"      East African trypanosomiasis is caused by Trypanosoma brucei rhodesiense, antelope and cattle are the primary reservoirs, it occurs mainly in savanna and woodland areas, and has been reported in tourists visiting game parks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/30\">",
"       30",
"      </a>",
"      ]. Both parasites are transmitted by tsetse flies (Glossina spp).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cutaneous and visceral leishmaniasis occur in relatively restricted areas of sub-Saharan Africa, especially Sudan, Kenya, Ethiopia and Somalia. Sandflies of the genus Phlebotomus are the vectors. Visceral leishmaniasis occurs both sporadically and in epidemics; a recent epidemic occurred among refugees from southern Sudan. The main reservoirs are rodents and small carnivores. Leishmania aethiopica is the principal cause of cutaneous leishmaniasis in the Ethiopian highlands and Kenya. The hyrax is the main reservoir. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./treatment-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Treatment of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42308?source=see_link\">",
"     \"Epidemiology and control of visceral leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21161?source=see_link\">",
"     \"Clinical manifestations and diagnosis of visceral leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43625?source=see_link\">",
"     \"Treatment of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Onchocerciasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onchocerciasis (river blindness) is caused by the roundworm Onchocerca volvulus and is transmitted to humans by Simulium blackflies. Endemic areas are widespread through parts of sub-Saharan Africa, determined by the distribution of the vector. Blackflies breed in fast flowing streams in both savanna and rain forest. The risk to short term travelers of developing onchocerciasis is small, although acquisition after only four to six weeks' exposure has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Typhus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both epidemic typhus (caused by Rickettsia prowazekii) and murine typhus (caused by Rickettsia typhi) are present in sub-Saharan Africa:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemic typhus is transmitted by the body louse, and human conditions that favor the proliferation of lice occur during cold weather (eg, rural East African highlands) and during war or natural disasters (eg, among refugees). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/29/38358?source=see_link\">",
"       \"Epidemic typhus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Murine typhus is transmitted to humans by rat or cat fleas, and occurs most commonly in urban settings. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27796?source=see_link\">",
"       \"The epidemiology and clinical manifestations of murine typhus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, tick typhus, caused by Rickettsia conorii, Rickettsia africae and others, occurs sporadically, particularly in east and southern Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/33\">",
"     33",
"    </a>",
"    ]. Its epidemiology is closely associated with ticks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chikungunya fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya fever has been reported in travelers to Zimbabwe and various islands in the Indian Ocean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/34\">",
"     34",
"    </a>",
"    ]. Other affected areas include Mombasa and Kenya. Infection is transmitted by the bite of an Aedes mosquito and the illness is characterized by sudden onset of fever and severe arthralgias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOODBORNE AND WATERBORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Travelers' diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sub-Saharan Africa is regarded as a high risk area for the development of travelers' diarrhea, with enterotoxigenic Escherichia coli being the most common pathogen identified (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 50 percent of European tourists to east Africa in 1995 developed diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cholera",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera outbreaks are frequent occurrences in sub-Saharan Africa. During 1999 a total of over 200,000 cases and more than 8500 deaths were reported from the region. During 2005 to 2006, large outbreaks of cholera have occurred in southern Sudan and in West Africa (Benin, Burkina Faso, Guinea, Guinea-Bissau, Mali, Mauritania, Niger and Senegal). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Typhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid fever is endemic throughout most of sub-Saharan Africa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations for travel\", section on 'Typhoid vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hepatitis A and hepatitis E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus is endemic throughout sub-Saharan Africa. Hepatitis E has been responsible for both outbreaks and sporadic cases of hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and is probably widespread in the region. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33976?source=see_link\">",
"     \"Hepatitis E virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H11#H11\">",
"     \"Immunizations for travel\", section on 'Hepatitis A vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Poliomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reservoirs of wild poliovirus exist in many areas of sub-Saharan Africa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H7672819#H7672819\">",
"     \"Immunizations for travel\", section on 'Poliovirus vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Schistosomiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis due to Schistosoma haematobium and Schistosoma mansoni is widespread in sub-Saharan Africa and is now recognized as a major hazard for travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/39\">",
"     39",
"    </a>",
"    ]. Transmission occurs through exposure to fresh water (lakes and slow moving rivers) in endemic regions, and many travelers are only diagnosed with the disease on post-travel screening. Lake Malawi, much of which has been incorrectly labeled as schistosomiasis-free, is a major source of infection in travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Paragonimiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endemic foci of the lung fluke Paragonimus westermani are present in west Africa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link\">",
"     \"Paragonimiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Dracunculiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guinea worm (Dracunculus medinensis) infection is prevalent only in the Sudan. The disease is prevalent in areas where people bathe and wade in water used also for drinking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Echinococcosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydatid disease continues to be relatively common in areas of Africa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=see_link\">",
"     \"Treatment of echinococcosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Meningococcal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sub-Saharan Africa has a unique pattern of epidemic meningococcal disease. Epidemics occur during the dry season in the \"meningitis belt\" (",
"    <a class=\"graphic graphic_figure graphicRef63287 \" href=\"mobipreview.htm?16/45/17110\">",
"     figure 4",
"    </a>",
"    ), the most affected countries being Chad, Nigeria, Burkina Faso, Mali, and Niger. Major epidemics occur every 5 to 10 years in this area, affecting hundreds of thousands of people.",
"   </p>",
"   <p>",
"    Most epidemics are caused by serogroup A and, less often, serogroup C. Both of these serogroups are covered by the polysaccharide meningococcal vaccine that is recommended for travelers to countries affected by meningococcal outbreaks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H1651582#H1651582\">",
"     \"Immunizations for travel\", section on 'Meningococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sub-Saharan Africa is the region of the world most affected by the",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    pandemic. In 2003, an estimated 26.6 million people in this region were living with HIV, including the 3.2 million who became infected during the past year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/41\">",
"     41",
"    </a>",
"    ]. The main mode of transmission in the region is heterosexual contact. Unprotected sex with locals carries the greatest risk of transmission to travelers to sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted disease is a major public health problem in parts of sub-Saharan Africa. Contact with sex workers involves a high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hepatitis B and hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus is highly endemic throughout sub-Saharan Africa (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    ). The prevalence of hepatitis C is also high in many regions (&gt;10 percent in some countries). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Plague",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the world's reported cases of plague over recent years have come from sub-Saharan Africa (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    ). Almost all reported cases have come from Madagascar and Tanzania, accounting for 2576 cases in 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/43\">",
"     43",
"    </a>",
"    ], although recent outbreaks have occurred in Malawi and Zambia and the Democratic Republic of Congo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies is endemic throughout sub-Saharan Africa and has been reported with increasing frequency over recent decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40121/abstract/44\">",
"     44",
"    </a>",
"    ]. The domestic dog plays a key role in maintenance and transmission of rabies, although other animals (eg, mongoose and fox) are important in some regions. Postexposure treatment is recommended following all potential exposures and prophylaxis should be considered by travelers spending significant periods of time in sub-Saharan Africa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H1652399#H1652399\">",
"     \"Immunizations for travel\", section on 'Rabies vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tuberculosis is relatively common in many parts of sub-Saharan Africa, short-term travelers from countries of low endemicity are generally not considered at increased risk of infection, and specific preventative measures are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     OTHER HAZARDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Snake bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venomous snakes are present throughout sub-Saharan Africa. The most important species include the saw-scaled or carpet viper (Echis spp), puff adder (Bitis arietans), and spitting cobra (Naja nigricollis, N. mossambica and others). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     High altitude disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many high altitude areas in sub-Saharan Africa, several of which are popular tourist destinations. Kilimanjaro (5895 m) is the highest peak in the African continent and is climbed by many travelers each year, including many with limited trekking or climbing experience. Traditional ascent itineraries are rapid and acute mountain sickness is common (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    ). Although unsubstantiated by hard data, the mountains of east Africa had the reputation of having the highest death rate due to altitude illness of any area of the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378793\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sub-Saharan Africa refers to the central region of the African continent between the Sahara Desert in the North to a latitude of about 20&ordm;S (",
"      <a class=\"graphic graphic_figure graphicRef68381 \" href=\"mobipreview.htm?21/52/22342\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a 2006 GeoSentinel report that described 4524 ill patients who had returned to developed countries after travel to sub-Saharan Africa, 70 percent presented within one month after returning from travel, and 18 percent required hospitalization. The primary manifestations in about 65 percent of returned travelers fell into four major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, and nondiarrheal gastrointestinal disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with a systemic febrile illness, 62 percent had malaria, 1 percent had dengue, 6 percent had a rickettsial infection, and no cause was reported in 28 percent.",
"     </li>",
"     <li>",
"      Among patients with acute diarrhea, 35 percent had parasitic infection (mostly giardiasis and amebiasis), 25 percent had bacterial infection (mostly Campylobacter, and less often Shigella and nontyphoidal Salmonella), a small number had viral infection, and 40 percent had unspecified acute diarrhea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surveillance data'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 GeoSentinel report, among ill travelers who had returned from sub-Saharan Africa, fever was present in 41 percent with the following distribution of causes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      49 percent had a systemic febrile illness, mostly due to malaria (42 percent).",
"     </li>",
"     <li>",
"      10 percent had a diarrheal illness.",
"     </li>",
"     <li>",
"      10 percent had a respiratory illness.",
"     </li>",
"     <li>",
"      19 percent had an undiagnosed febrile illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surveillance data'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria is a major risk for most travelers to sub-Saharan Africa. Endemic areas exist in all countries in this region except for the islands of R&eacute;union and Seychelles, and at altitudes over 2600 m. Except for Mauritius and Cape Verde, Plasmodium falciparum is the predominant cause of malaria and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      -resistance is widespread. Within endemic areas, transmission occurs year-round. Country-specific risk areas are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef59126 \" href=\"mobipreview.htm?36/31/37373\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yellow fever is endemic throughout most of sub-Saharan Africa (",
"      <a class=\"graphic graphic_figure graphicRef74437 \" href=\"mobipreview.htm?11/14/11496\">",
"       figure 2",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"       Yellow fever vaccine",
"      </a>",
"      is required for entry into most countries in sub-Saharan Africa. In addition, many neighboring countries of endemic regions require yellow fever certificates for travelers coming from infected areas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Yellow fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other endemic arthropod-borne diseases include dengue, Rift Valley fever, African trypanosomiasis, leishmaniasis, onchocerciasis, typhus, and Chikungunya fever. In addition to yellow fever, dengue, and Rift Valley fever, other causes of viral hemorrhagic fever are Lassa fever, Ebola virus, Marburg virus, and Crimean-Congo hemorrhagic fever. Some of these viruses (eg, Ebola virus) are transmitted by contact with body fluid from infected humans or animals. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Arthropod-borne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sub-Saharan Africa is regarded as a high risk area for the development of travelers' diarrhea, with enterotoxigenic Escherichia coli being the most common pathogen identified. Other endemic foodborne and waterborne diseases include cholera, typhoid, hepatitis A, hepatitis E, poliovirus, schistosomiasis, paragonimiasis, dracunculiasis, and echinococcus. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Foodborne and waterborne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sub-Saharan Africa has a unique pattern of epidemic meningococcal disease. Epidemics occur during the dry season in the \"meningitis belt\" (",
"      <a class=\"graphic graphic_figure graphicRef63287 \" href=\"mobipreview.htm?16/45/17110\">",
"       figure 4",
"      </a>",
"      ), the most affected countries being Chad, Nigeria, Burkina Faso, Mali, and Niger. Major epidemics occur every 5 to 10 years in this area, affecting hundreds of thousands of people. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Meningococcal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sub-Saharan Africa is the region of the world most affected by the",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      pandemic. The main mode of transmission in the region is heterosexual contact. Hepatitis B and other sexually transmitted diseases are also a major public health problem in parts of sub-Saharan Africa. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'HIV infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Hepatitis B and hepatitis C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Other sexually transmitted diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risks to travelers include hepatitis C, plague, rabies, snake bites, and high altitude disease. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Hepatitis B and hepatitis C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Plague'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Rabies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Other hazards'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/1\">",
"      Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/2\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/3\">",
"      Yellow fever, 1996-1997 part I. WHO Weekly Epidemiol Rec 1998; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Imported Lassa fever--New Jersey, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/5\">",
"      Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Rift Valley fever outbreak--Kenya, November 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/7\">",
"      Faye O, Diallo M, Diop D, et al. Rift Valley fever outbreak with East-Central African virus lineage in Mauritania, 2003. Emerg Infect Dis 2007; 13:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Rift Valley Fever--East Africa, 1997-1998. MMWR Morb Mortal Wkly Rep 1998; 47:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/9\">",
"      Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999; 179 Suppl 1:ix.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/10\">",
"      Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/11\">",
"      Heffernan RT, Pambo B, Hatchett RJ, et al. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogoou&eacute;-Ivindo region, Northeastern Gabon, 1997. J Infect Dis 2005; 191:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/12\">",
"      Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/13\">",
"      Formenty P, Leroy EM, Epelboin A, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis 2006; 42:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/14\">",
"      Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006; 355:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of Marburg virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/16\">",
"      Peters CJ. Marburg and Ebola--arming ourselves against the deadly filoviruses. N Engl J Med 2005; 352:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/17\">",
"      Ndayimirije N, Kindhauser MK. Marburg hemorrhagic fever in Angola--fighting fear and a lethal pathogen. N Engl J Med 2005; 352:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/18\">",
"      Borchert M, Mulangu S, Swanepoel R, et al. Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis 2006; 12:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/19\">",
"      Daddario-DiCaprio KM, Geisbert TW, Str&ouml;her U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/20\">",
"      Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/21\">",
"      Erg&ouml;n&uuml;l O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/22\">",
"      Erg&ouml;n&uuml;l O, Celikba A, Dokuzoguz B, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/23\">",
"      Swanepoel R, Shepherd AJ, Leman PA, et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am J Trop Med Hyg 1987; 36:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/24\">",
"      Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 Suppl 4:S801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/25\">",
"      Fisher-Hoch SP, Khan JA, Rehman S, et al. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995; 346:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/26\">",
"      Ergonul O, Tuncbilek S, Baykam N, et al. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006; 193:941.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention and World Health Organization. Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting, 1998. WHO/EMC/EST/98.2. file://www.who.int/csr/resources/publications/ebola/WHO_EMC_ESR_98_2_EN/en/ (Accessed on September 05, 2008).",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Crimean-Congo hemorrhagic fever. file://www.who.int/mediacentre/factsheets/fs208/en/ (Accessed on September 05, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/29\">",
"      Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/30\">",
"      Ponce-de-Le&oacute;n S, Lisker-Melman M, Kato-Maeda M, et al. Trypanosoma brucei rhodesiense infection imported to Mexico from a tourist resort in Kenya. Clin Infect Dis 1996; 23:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/31\">",
"      Pryce D, Behrens R, Davidson R, et al. Onchocerciasis in members of an expedition to Cameroon: role of advice before travel and long term follow up. BMJ 1992; 304:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/32\">",
"      Encarnacion CF, Giordano MF, Murray HW. Onchocerciasis in New York City. The Moa-Manhattan connection. Arch Intern Med 1994; 154:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/33\">",
"      Raoult D, Fournier PE, Fenollar F, et al. Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. N Engl J Med 2001; 344:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Chikungunya fever diagnosed among international travelers--United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2006; 55:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/35\">",
"      Steffen R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986; 8 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/36\">",
"      Angst F, Steffen R. Update on the Epidemiology of Traveler's Diarrhea in East Africa. J Travel Med 1997; 4:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/37\">",
"      Rioche M, Dubreuil P, Kouassi-Samgare A, et al. [Incidence of sporadic hepatitis E in Ivory Coast based on still problematic serology]. Bull World Health Organ 1997; 75:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/38\">",
"      Hyams KC, Purdy MA, Kaur M, et al. Acute sporadic hepatitis E in Sudanese children: analysis based on a new western blot assay. J Infect Dis 1992; 165:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/39\">",
"      Jelinek T, Nothdurft HD, L&ouml;scher T. Schistosomiasis in Travelers and Expatriates. J Travel Med 1996; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/40\">",
"      Potasman I I, Pick N, Abel A, Dan M. Schistosomiasis Acquired in Lake Malawi. J Travel Med 1996; 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS. AIDS epidemic update: 2003. Geneva: UNAIDS/WHO, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/42\">",
"      Eng TR, O'Brien TR, Bernard KW, et al. HIV-1 and HIV-2 Infections Among U.S. Peace Corps Volunteers Returning from West Africa. J Travel Med 1995; 2:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/43\">",
"      Human plague in 1997. Wkly Epidemiol Rec 1999; 74:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40121/abstract/44\">",
"      Cleaveland S. Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London, 20 March 1997. Epidemiology and control of rabies. The growing problem of rabies in Africa. Trans R Soc Trop Med Hyg 1998; 92:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3887 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40121=[""].join("\n");
var outline_f39_11_40121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4378793\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURVEILLANCE DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ARTHROPOD-BORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Yellow fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dengue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other viral hemorrhagic fevers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lassa fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rift Valley fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ebola virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Marburg virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Crimean-Congo hemorrhagic fever (CCHF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Typhus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOODBORNE AND WATERBORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cholera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Typhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hepatitis A and hepatitis E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Poliomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Dracunculiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Meningococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hepatitis B and hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Plague",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Rabies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      OTHER HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Snake bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      High altitude disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4378793\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3887|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/52/22342\" title=\"figure 1\">",
"      Map of sub-Saharan Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/14/11496\" title=\"figure 2\">",
"      Yellow fever endemic zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/57/35729\" title=\"figure 3\">",
"      African trypanosomiasis epidemic areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/45/17110\" title=\"figure 4\">",
"      Meningitis belt map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/31/37373\" title=\"table 1\">",
"      Endemic malaria in Africa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21161?source=related_link\">",
"      Clinical manifestations and diagnosis of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38681?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1624?source=related_link\">",
"      Diagnosis and treatment of Ebola and Marburg hemorrhagic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/29/38358?source=related_link\">",
"      Epidemic typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42308?source=related_link\">",
"      Epidemiology and control of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19721?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13895?source=related_link\">",
"      Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29768?source=related_link\">",
"      Pathogenesis of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/9/27796?source=related_link\">",
"      The epidemiology and clinical manifestations of murine typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-of-cutaneous-leishmaniasis?source=related_link\">",
"      Treatment of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=related_link\">",
"      Treatment of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43625?source=related_link\">",
"      Treatment of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40122="Treatment of non-muscle-invasive bladder cancer";
var content_f39_11_40122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"27\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of non-muscle-invasive bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Michael A O'Donnell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/11/40122/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/11/40122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, bladder cancer accounted for 386,000 cases and 150,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/1\">",
"     1",
"    </a>",
"    ]. In developed areas of the world, such as North America and western Europe, these bladder cancers are predominantly urothelial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 70 percent of new urothelial (transitional cell) bladder cancer cases are classified as non-muscle-invasive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/2\">",
"     2",
"    </a>",
"    ]. This category of bladder cancer includes Ta (papillary), T1 (submucosal invasive) tumors (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ), and Tis (carcinoma in situ, CIS) which account for approximately 70, 20 and 10 percent of non-muscle invasive cancers, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link\">",
"     \"Pathology of bladder neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment generally is a complete cystoscopic (transurethral) resection of all visible bladder tumor (TURBT). This is often followed by adjuvant intravesical therapy.",
"   </p>",
"   <p>",
"    The management of non-muscle invasive bladder cancer is discussed here. The clinical presentation, diagnosis, and staging of bladder cancer, and an overview of the treatment of urothelial bladder cancer are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2759?source=see_link\">",
"     \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 40 to 80 percent of non-muscle invasive bladder cancers recur within 6 to 12 months if managed with a TURBT without additional therapy, and 10 to 25 percent will develop muscle-invasive, regional, or metastatic disease. Thus, more aggressive therapy is often required even though an initial complete transurethral resection is possible.",
"   </p>",
"   <p>",
"    The most important prognostic factors are histologic stage and grade. Other factors that have been assessed include the presence of multicentric disease, the frequency of recurrence, the tumor size, and the presence or absence of concomitant CIS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-muscle invasive bladder cancers are classified into three groups, Ta, Tis (also referred to as carcinoma in situ, CIS), and T1 lesions, based upon their growth pattern and depth of invasion (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathology of bladder neoplasms\", section on 'Pathologic tumor staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Ta tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ta tumors are noninvasive papillary lesions that are confined to the urothelium and have not penetrated the basement membrane. These papillary tumors usually present as low-grade lesions that frequently recur multiple times prior to becoming invasive. The natural history of patients with Ta tumors without other evidence of invasive disease or Tis was illustrated by a retrospective series of 363 patients, in which only 6 percent eventually died of bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/3\">",
"     3",
"    </a>",
"    ]. The fraction of patients who eventually progress to a high-grade lesion and require more aggressive treatment ranges from 6 to 28 percent in different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Tis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tis (also called carcinoma in situ [CIS]) is characterized by severe cellular dysplasia in the absence of discrete tumor formation. Areas of mucosal involvement with Tis are often found in association with invasive disease. The presence of Tis in the mucosa adjacent to a Ta or T1 tumor appears to increase the risk for muscle invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential prognostic significance associated with Tis is illustrated by a multicenter series 243 patients who underwent radical cystectomy for carcinoma in situ without more invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/7\">",
"     7",
"    </a>",
"    ]. Staging based upon the cystectomy specimen revealed that Tis, T0, or Ta in 48, 8, and 8 percent of cases, respectively. However, T1, T2, T3, and T4 disease was detected in 13, 12, 5, and 6 percent of cases, respectively. Lymphovascular invasion and positive lymph nodes were found in 9 and 6 percent, respectively.",
"   </p>",
"   <p>",
"    The presence of Tis without invasive urothelial cancer is associated with a high incidence of progression to invasive disease, even after transurethral resection and treatment in intravesical BCG. In a retrospective, single institution series of 155 patients managed with transurethral resection and intravesical bacillus Calmette-Guerin (BCG), the five-year cumulative incidence of progression to cT1 or higher disease was 45 percent (95% CI 37-55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffuse involvement of the mucosa with Tis is associated with particularly aggressive disease. Invasive bladder cancer develops in 60 to 80 percent of such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     T1 lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;T1 tumors are by definition invasive cancers and are characterized by extension into the underlying lamina propria (also known as the submucosa) but without involvement of the muscularis propria, the true detrusor muscle of the bladder. Virtually all T1 tumors are high-grade, and one-half have associated Tis. Recurrence rates by one, three, and five years are 50, 70 to 80, and 90 percent, respectively, and 20 to 25 percent progress to invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. T1 lesions occurring in patients who had a prior tumor resection for Tis or Ta disease have a higher frequency of progression after BCG treatment compared to those with an initial presentation with T1 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risk of progression, T1 tumors are generally treated with intravesical therapy, such as bacillus Calmette-Guerin (BCG), which reduces the recurrence rate by 30 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and may also reduce progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Intravesical BCG'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to tumor stage (Tis, Ta, or T1), histologic grade influences the rate of recurrence and ultimately survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The importance of histologic grade was illustrated in a retrospective series of 249 patients with Ta or T1 lesions who were treated with local resection, without adjuvant intravesical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/17\">",
"     17",
"    </a>",
"    ]. Among patients with grade 1, 2 or 3 lesions, invasive cancer developed in 2, 11, and 45 percent, respectively. In another series of 252 patients with non-muscle invasive bladder cancer, multivariate analysis revealed that the grade of the initial tumor was the only significant predictor of subsequent invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with grade 1 or grade 2 papillary (Ta) lesions who remain free of recurrence for at least five years usually have a good prognosis. In a series of 198 such patients diagnosed between 1991 and 1996, 89 percent remained free of recurrence five years after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/20\">",
"     20",
"    </a>",
"    ]. However, active surveillance is still required because of the risk of recurrence.",
"   </p>",
"   <p>",
"    In 2004, the World Health Organization revised its 1973 grading system in an attempt to improve interobserver agreement and provide better prognostic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/21\">",
"     21",
"    </a>",
"    ]. The new system employs the terms papillary urothelial neoplasm of low malignant potential (PUNLMP), low-grade urothelial carcinoma, and high-grade urothelial carcinoma. Because there remains disagreement among both pathologists and clinicians about the merits of the new classification system, the older system is still commonly used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link\">",
"     \"Pathology of bladder neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multicentricity and frequency of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have multiple papillary tumors at the time of presentation have higher rates of both non-muscle invasive and invasive recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/17,18,22\">",
"     17,18,22",
"    </a>",
"    ], but not necessarily worse survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, the risk in one series for progression to muscle-invasive disease for multiple and solitary lesions was 14 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular markers may provide an additional way to identify non-muscle invasive bladder cancers that are likely to progress to muscle invasive or high-grade disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The earliest studies focused on chromosomal abnormalities, and these provided the basis for identifying specific genetic alterations.",
"   </p>",
"   <p>",
"    The presence of mutations in fibroblast growth factor receptor 3 (FGFR3) appears to identify a subgroup of patients with a favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/21,26,27\">",
"     21,26,27",
"    </a>",
"    ]. Although some studies have suggested that abnormalities in p53 are associated with a less favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], a prospective evaluation of p53 status based upon immunohistochemistry in 499 patients treated with radical cystectomy for stage pT1N0 or pT2NO urothelial cancer did not observe a difference in either recurrence rate or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link&amp;anchor=H1072936968#H1072936968\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\", section on 'Contemporary trials'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Gene expression profiling may offer another approach to identifying those patients who are most likely to progress to muscle-invasive disease and thus would benefit from more aggressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have analyzed large retrospective series in an attempt to classify patients according to their risk of disease recurrence and progression to invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a patient to be considered at low risk, all of the following features should be present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial presentation with a non-muscle invasive Ta tumor",
"     </li>",
"     <li>",
"      Greater than one year between tumor recurrences",
"     </li>",
"     <li>",
"      Three or fewer lesions, all of which are small (&le;3 cm), with a papillary appearance, and on a fine stalk",
"     </li>",
"     <li>",
"      No invasion of the lamina propria and no associated CIS (Ta only and not T1 or Tis, (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      )) and well or moderately differentiated histology (grade 1 to 2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, the presence of",
"    <strong>",
"     any",
"    </strong>",
"    of the following features is associated with an increased risk of recurrence or progression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple papillary recurrences within a short time period (eg, two or more tumor recurrences in a given year) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      More than three lesions, or any one tumor &gt;3 cm in diameter, sessile, or with a thick stalk",
"     </li>",
"     <li>",
"      Invasion of the lamina propria (T1 tumor, (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      )) or poorly differentiated histology (grade 3)",
"     </li>",
"     <li>",
"      Incomplete resection due to diffuse bladder involvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unfavorable location",
"     </li>",
"     <li>",
"      The presence of diffuse Tis alone, or Tis in association with papillary tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A",
"    <a class=\"external\" href=\"file://www.eortc.be/tools/bladdercalculator/default.htm\">",
"     quantitative calculator",
"    </a>",
"    to more accurately predict the risk of both recurrence and progression has been developed by the European Organization for Research and Treatment of Cancer (EORTC), based upon data from nearly 2600 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Risk is calculated using a scoring system based on six factors: number of tumors, tumor size, prior recurrence rate (ie, first time occurrence versus recurrence &gt;1 year from prior diagnosis versus recurrent tumor &lt;1 year from prior diagnosis), T category, carcinoma in situ, and grade. The five-year probabilities of recurrence or progression, based on total score, ranged from 30 to 80 percent and 1 to 45 percent, respectively.",
"   </p>",
"   <p>",
"    Patients with the lowest risk disease are usually managed by TURBT alone, often with a single dose of immediate post-operative chemotherapy as recommended by guidelines from both the American Urological Association (AUA) and the European Association of Urology (EAU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Further courses of intravesical therapy are generally recommended for patients with intermediate to high-risk non-muscle invasive bladder tumors in an effort to decrease the risk of recurrence and need for cystectomy. Careful surveillance following treatment is recommended for both low- and high-risk patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Intravesical therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H42\">",
"     'Posttreatment management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of patients with non-muscle invasive bladder cancer includes accurate staging and resection of known areas of disease involvement. Incorporation of information about the depth of invasion, histologic grade, and the presence or absence of multicentric disease are important factors in determining whether management should consist of TURBT alone, TURBT plus intravesical therapy, or cystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transurethral resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of non-muscle invasive bladder tumors is a complete TURBT, which is usually carried out at the time of diagnosis. Many patients can be successively managed with a localized resection, and more aggressive surgical resection should be deferred whenever possible. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Indications for cystectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    TURBT in patients suspected of high-grade or T1 disease should include biopsies of apparently uninvolved areas of the bladder mucosa and prostatic urethra to rule out occult involvement with Tis. An examination under anesthesia (EUA) should also be performed, since the presence of a palpable mass suggests muscle invasive disease.",
"   </p>",
"   <p>",
"    Although clinical staging with TURBT and EUA generally dictates management, it has limitations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 30 percent of T1 tumors will be understaged by TURBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Thus, a repeat TURBT is generally recommended to decrease the likelihood of understaging in patients whose tumors involve the lamina propria, even if the initial resection was thought to be complete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/40,41,44-48\">",
"       40,41,44-48",
"      </a>",
"      ]. In a retrospective series of 150 cases, residual bladder tumors were found in 76 percent of patients subjected to a restaging procedure, while muscle-invasive disease was found in 49 percent of patients who did not have detrusor muscle present in the initial resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Up to 30 percent of non-muscle invasive bladder tumors are multifocal at presentation, probably because genetic abnormalities over the entire urothelial surface (the \"field cancerization\" effect) predispose to multifocal carcinogenesis. This hypothesis is supported by the observation that multifocal non-muscle invasive bladder tumors appear to be monoclonal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/49\">",
"       49",
"      </a>",
"      ], and the genetic changes in tumors are also present in adjacent morphologically normal bladder mucosa. The majority of patients with non-muscle invasive bladder cancer will develop new tumors over time, and 15 to 30 percent of these will be invasive. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35367?source=see_link&amp;anchor=H2#H2\">",
"       \"Chemoprevention of bladder cancer\", section on 'Rationale'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite complete TURBT, up to 80 percent of patients with high-risk tumors will recur within 12 months. Because of these high recurrence rates, adjuvant intravesical therapy is widely used in this population. For these patients, a restaging TURBT should be considered. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Intravesical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Restaging TURBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high-risk non-muscle invasive bladder cancer who are candidates for intravesical BCG should undergo a repeat cystoscopy with biopsies of previous areas of involvement prior to therapy. This approach is important both to detect previously undiagnosed disease and to reduce the tumor burden prior to BCG immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/45,50,51\">",
"     45,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of this approach was illustrated by a retrospective single-institution series of 347 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/45\">",
"     45",
"    </a>",
"    ]. Of the 132 patients who did not have a repeat endoscopy, 57 percent had residual or recurrent disease at the first cystoscopy following BCG therapy, and 34 percent later had progression to invasive disease. In contrast, only 29 percent of the 215 patients who had a restaging TURBT had residual or recurrent disease following BCG treatment, and only 7 percent ultimately had progression. A similar beneficial improvement in recurrence for re-resected patients was also obtained in a prospective randomized trial involving stage T1 cancer patients in which the chemotherapeutic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluorescence endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence endoscopy after intravesical instillation of a porphyrin such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9395?source=see_link\">",
"     hexaminolevulinate",
"    </a>",
"    or 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) may be more effective than white light endoscopic resection for the detection of multifocal tumors, thereby improving outcomes of TURBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/53-60\">",
"     53-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized clinical trials have yielded conflicting results, with at least three trials demonstrating that fluorescence endoscopy prolongs recurrence-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/54,55,61\">",
"     54,55,61",
"    </a>",
"    ], while two trials failed to detect an advantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The range of results is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest positive trial, 814 patients suspected of having bladder cancer at increased risk of recurrence were randomly assigned to cystoscopy with or without intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9395?source=see_link\">",
"       hexaminolevulinate",
"      </a>",
"      one hour prior to the procedure. In the group assigned to fluorescence cystoscopy, patients first were examined with white light and then underwent reexamination with blue light before and after TURBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Among the patients examined with fluorescence cystoscopy, 47 of 286 patients (16 percent) with at least one Ta or T1 lesion had one or more additional lesions detected at reexamination with blue light. Furthermore, at the nine month follow-up, there was a statistically significant decrease in the recurrence rate in those who initially were managed with fluorescence endoscopy (128 of 271 [47 percent] versus 157 of 280 [56 percent] in the white light group). The results of this trial were the basis for the Food and Drug Administration approval of hexaminolevulinate.",
"     </li>",
"     <li>",
"      In a multicenter trial, 301 patients with suspected non-muscle invasive bladder cancer were randomly assigned to TURBT using either fluorescence endoscopy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"       aminolevulinic acid",
"      </a>",
"      or white light [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/55\">",
"       55",
"      </a>",
"      ]. All patients with non-muscle-invasive tumor underwent repeat endoscopy with white light six weeks later. At that time, significantly fewer patients whose initial procedure used ALA had residual tumor (5 versus 25 percent with white light). On subsequent follow-up, the relapse-free survival was significantly higher in patients who had been evaluated with fluorescence endoscopy (88 versus 73, 84 versus 64, 79 versus 54, and 71 versus 45 percent at two, four, six, and eight years, respectively).",
"     </li>",
"     <li>",
"      In contrast, in another trial, 300 patients were randomly assigned to cystoscopy with or without 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"       aminolevulinic acid",
"      </a>",
"      ; both observers and pathologists were blinded to study assignment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/62\">",
"       62",
"      </a>",
"      ]. There was no significant difference in the number of tumors (1.7 with fluorescence versus 1.8 with white light). At 12 months, there was no difference between groups based upon recurrence-free or progression-free survival rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improved early detection and treatment of tumors needs to be balanced by a slightly higher false-positive rate (mainly due to inflammation and scarring), the requirement for a special lens system, the need to instill the photosensitizer one hour prior to cystoscopy, and the need for rigid rather than flexible cystoscopy, as well as the higher cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications for cystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystectomy is indicated in patients for whom the initial staging indicates muscle-invasive (T2) disease (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). Cystectomy is also indicated for patients with symptoms related to the bladder pathology (eg, urinary frequency, hemorrhage) that cannot be adequately managed medically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, radical cystectomy may be indicated for earlier stage disease in high-risk patients to prevent progression to T2 disease, which is associated with a poorer prognosis.",
"   </p>",
"   <p>",
"    The potential importance of cystectomy prior to the development of T2 disease was illustrated by a cohort of 402 consecutive patients who underwent cystectomy for bladder cancer at a single-institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/64\">",
"     64",
"    </a>",
"    ]. The cohort was divided into three groups based upon the indication for cystectomy: patients with high-risk disease (clinical stage Tis or T1), those who presented with Tis or T1 disease but had then progressed to clinical T2 involvement while being treated conservatively (the \"early\" T2 group), and those who presented with T2 disease de novo.",
"   </p>",
"   <p>",
"    There was no survival benefit when cystectomy was deferred as part of a strategy to conserve the bladder until T2 disease developed (the \"early\" T2 group), compared to those presenting with de novo T2 involvement. The three-year disease-specific survival was significantly better for patients having cystectomy for clinical stage Tis or T1 disease, and there was no difference in outcome between those who developed T2 disease while under close observation and those who presented with T2 disease (76 versus 63 and 64 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Non-muscle invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystectomy should be considered in patients with multiple tumors or frequent recurrences, particularly if tumors recur within a short period of time despite treatment with intravesical BCG. In addition, non-muscle invasive tumors of the prostatic urethra are frequently managed by cystectomy, particularly if a complete resection cannot be accomplished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     T1 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management with TURBT alone is generally inadequate, with recurrence rates at one, three, and five years of approximately 50, 80, and 90 percent, respectively. Treatment with intravesical BCG after TURBT results in 70 percent five-year survival for T1 tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/11\">",
"     11",
"    </a>",
"    ]. This is similar to the results achieved with immediate radical cystectomy. However, cystectomy is appropriate for patients who relapse with recurrent T1 tumors within 6 to 12 months after combined treatment with TURBT and intravesical BCG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INTRAVESICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical therapy permits high local concentrations of a therapeutic agent within the bladder, potentially destroying viable tumor cells that remain following TURBT and preventing tumor implantation. The decision to proceed with intravesical therapy depends upon various risk factors and the likelihood of whether or not the patient will have a recurrence. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravesical therapy is generally used in the adjuvant setting, to prevent further recurrence. Less commonly, intravesical therapy may be given for residual disease that remains in the bladder following TURBT. This situation is relatively infrequent, except in cases with diffuse CIS. Indeed, BCG is considered the treatment of choice for patients with CIS. In a meta-analysis of 700 patients with CIS, 68 percent achieved a complete response with BCG versus 51 percent with chemotherapy. Furthermore the long-term 3.6-year durability of response to BCG was significantly better than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (47 versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All intravesical therapies can cause symptoms of bladder irritation (dysuria and frequency). In addition, systemic effects may occur if the agent is absorbed through the mucosa. The latter phenomenon depends partly upon the size of the molecule and the pH in the bladder at the time of instillation.",
"   </p>",
"   <p>",
"    The presence of mucosal damage at the time of instillation can permit systemic absorption of the agent. Deferring intravesical therapy for two to three weeks following TURBT allows healing and reduces the likelihood of severe local or systemic toxicities.",
"   </p>",
"   <p>",
"    The most commonly used agent for intravesical therapy is Bacillus Calmette-Guerin (BCG). A number of other agents also have activity, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    , the anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , interferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INTRAVESICAL BCG",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients with stage T1 tumors (and select patients with Tis or Ta tumors in whom the original staging surgery was inadequate), we recommend a course of intravesical BCG immunotherapy following a restaging TURBT rather than intravesical chemotherapy. BCG, a live attenuated form of Mycobacterium bovis, is the most commonly used agent for intravesical therapy. A number of other intravesical agents have been compared to BCG, but none has proved consistently superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the exact mechanism of its antitumor action is unknown, intravesical instillation of BCG triggers a variety of local immune responses which appear to correlate with antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravesical BCG causes a mononuclear cell infiltrate that consists predominantly of CD4 T cells and macrophages.",
"     </li>",
"     <li>",
"      BCG treatment is associated with the presence of interferon-gamma (IFNg) in the bladder. IFNg induces bladder cancer cell expression of class II MHC molecules, such as HLA-DR and intercellular adhesion molecule (ICAM)-1, which are absent prior to treatment. IFN-gamma also can cause bladder tumor cells to become sensitive targets for lymphokine-activated killer (LAK) cells and antigen-presenting cells for BCG.",
"     </li>",
"     <li>",
"      Cytokine levels, such as interleukin (IL)-1, IL-2, IL-6, IL-8, IL-12, IFNg, tumor necrosis factor (TNF)-alpha, and tumor necrosis factor apoptosis inducing ligand (TRAIL) are increased in the urine following treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immune activation may persist for a number of months. In one study of uncomplicated intravesical instillation in 49 patients, BCG was detected in 96, 68 and 27 percent of urine specimens from two hours, 24 hours, and seven days following instillation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/73\">",
"     73",
"    </a>",
"    ]. 16S ribosomal DNA was demonstrated in bladder wall biopsy specimens up to 24 months later in 4 to 38 percent by polymerase chain reaction (PCR). The persistence of BCG in the bladder may facilitate an ongoing immune activation but also potentially increases the risk of a late systemic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"     \"Complications of intravesical BCG immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BCG may also directly suppress growth of tumor cells in a dose-dependent fashion. One study has shown that heat-inactivated BCG can cause this same effect although to a lesser degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCG is typically instilled into the bladder weekly for six weeks. Each dose consists of a vial of reconstituted Theracys&reg; (81 mg) or one 2 mL ampule of TICE&reg; BCG (50 mg), plus 50 mL of sterile saline injected into the bladder through a catheter and retained for two hours.",
"   </p>",
"   <p>",
"    To diminish the risk of systemic infection, intravesical BCG should not be administered to patients with traumatic catheterization, active cystitis, or persistent gross hematuria following TURBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"     \"Complications of intravesical BCG immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several trials suggest that a lower dose of BCG may be as effective but less toxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. The effect of dose was illustrated by a trial in which 155 patients with non-muscle invasive bladder cancer (T1 grade 3 or Tis, (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    )) were randomly assigned to six weekly instillations of standard or reduced dose BCG (81 and 27 mg, respectively) following complete TURBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/76\">",
"     76",
"    </a>",
"    ]. At a median follow-up of 61 months, there were no differences between the groups with respect to disease recurrence, time to recurrence, need for deferred cystectomy, or disease-specific survival. Rates of grade 3 or 4 toxicity were lower with the reduced dose (local, 37 versus 50 percent; systemic, 4 versus 16 percent, respectively).",
"   </p>",
"   <p>",
"    Although these results are encouraging, further confirmatory trials are needed before a reduced dose of BCG can be considered standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical BCG is the most efficacious agent for non-muscle invasive bladder cancer. BCG therapy has been shown to delay (although not necessarily prevent) tumor progression to a more advanced stage, decrease the need for subsequent cystectomy, and improve overall survival.",
"   </p>",
"   <p>",
"    In a systematic review, the activity of intravesical BCG was analyzed in six randomized trials that included 585 eligible patients with Ta or T1 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/79\">",
"     79",
"    </a>",
"    ]. Those treated with TURBT plus BCG had significantly fewer recurrences at 12 months compared to those managed with TURBT alone (odds ratio 0.30; 95% CI 0.21-0.43).",
"   </p>",
"   <p>",
"    Patients with high-risk bladder cancer who are disease-free following an induction course of BCG therapy have a better prognosis than those in whom residual disease is detected. In an analysis of 341 patients who were treated with a course of induction BCG and did not receive maintenance therapy, the five-year survival was better for those who were disease-free (77 versus 62 percent in those who were not disease-free, hazard ratio 0.60, 95% CI 0.44-0.81) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of maintenance BCG for longer than six weeks has been considered controversial. Longer treatment may further delay tumor recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. However, the frequency of complications is higher, and four of five randomized studies have shown no significant impact of maintenance treatment on tumor progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/81-84\">",
"     81-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest trial, from the Southwest Oncology Group (SWOG), was the only report to show a possible benefit from maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/85\">",
"     85",
"    </a>",
"    ]. In this trial, 660 patients with high-risk disease were treated with a six-week induction course of BCG following TURBT. At three months, 550 patients were randomly assigned to receive either no additional BCG or maintenance BCG (each week for three weeks given at 3, 6, 12, 18, 24, 30, and 36 months after the initiation of induction therapy).",
"   </p>",
"   <p>",
"    Although maintenance therapy was associated with significantly better median recurrence-free survival (77 versus 36 months without BCG) in this trial, the five-year survival rate was not significantly improved (83 versus 78 percent). No toxicities greater than grade 3 were noted in the 243 patients in the maintenance therapy arm, but cumulative toxicity resulted in only 16 percent of patients completing the three-year course of maintenance therapy. However, improvement in the rate of completing BCG therapy has been improved with reduction in the dose of BCG during maintenance therapy and the use of the fluoroquinolone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    given 8 and 20 hours after BCG dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the AUA and EAU bladder cancer guidelines commissions now recommend at least a year of BCG maintenance therapy for all high-risk patients who initiate with BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The rationale for this recommendation has been a series of meta-analyses demonstrating that the superior results in terms of prevention of recurrence and progression with BCG compared to chemotherapy are only observed in studies in which at least a year of maintenance therapy is provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/16,65,68,88\">",
"     16,65,68,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A repeat cystoscopy is indicated approximately six weeks after completing the induction cycle with BCG (three months after the start of treatment). For patients with high-risk tumors, rebiopsy of the original tumor sites or random biopsies of the bladder are often performed.",
"   </p>",
"   <p>",
"    If an initial course of intravesical BCG is unsuccessful, based upon either recurrent visible tumor or a positive biopsy or urine cytology, a repeat induction course of six weekly BCG treatments should be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/89\">",
"     89",
"    </a>",
"    ]. The diagnosis of BCG-refractory disease, and consideration of alternative therapies, requires a minimum treatment and follow-up time of six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 70 to 86 percent survival rate at four to five years following BCG is similar that achieved after immediate cystectomy and supports the choice of TURBT plus BCG rather than cystectomy for the initial management in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Although additional late relapses are observed, intravesical BCG does delay tumor progression and death in patients who present with non-muscle invasive bladder cancer.",
"   </p>",
"   <p>",
"    The long-term outcome following intravesical BCG therapy for non-muscle invasive bladder cancer has been assessed in a number of trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. As an example, 86 high-risk patients (Ta, Tis, or T1) were randomly assigned to BCG or no BCG following TURBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/93\">",
"     93",
"    </a>",
"    ]. At 10-year follow-up, the progression-free rate was longer for patients who had received BCG (62 versus 37 percent without BCG). Disease-specific survival was also significantly increased (75 versus 55 percent).",
"   </p>",
"   <p>",
"    Similar results have been reported in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. As an example, in one report of 98 patients with high-risk or recurrent non-muscle invasive bladder cancer and a minimum follow-up of ten years, 67 percent were progression-free, 59 percent had a retained bladder, and the disease-specific survival was 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a Cochrane database review of six randomized trials involving 585 eligible patients, toxicities associated with intravesical BCG included frequency (71 percent), cystitis (67 percent), fever (25 percent), and hematuria (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/79\">",
"     79",
"    </a>",
"    ]. There were no reported BCG-associated deaths.",
"   </p>",
"   <p>",
"    In addition to acute toxicities, both localized and systemic infectious complications can occur after intravesical administration of BCG. The infectious complications of intravesical BCG are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=see_link&amp;anchor=H29#H29\">",
"     \"Cystitis in patients with cancer\", section on 'BCG immunotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"     \"Complications of intravesical BCG immunotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To diminish the risk of systemic infection, intravesical BCG should not be administered to patients with traumatic catheterization, active cystitis, or persistent gross hematuria following TURBT, which appears to be associated with the greatest risk of systemic infection with BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/75\">",
"     75",
"    </a>",
"    ]. The presence of a prosthetic device (pacemaker, artificial heart valve, orthopedic hardware) is not an absolute contraindication to intravesical BCG. In a series of 143 patients with a prosthetic device (part of a larger, prospective cohort of 1045 patients) who were treated with intravesical BCG, there were three cases in which BCG had to be discontinued because of fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/96\">",
"     96",
"    </a>",
"    ]. In all three cases, fever resolved within 24 hours without long-term complications. Furthermore, this rate of fever was no different than what occurred in patients without prosthetic devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Interactions with statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins (HMG CoA reductase inhibitors) are known to have immunosuppressive effects that might theoretically counteract the immunotherapeutic effect of BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Whether or not this has clinical implications for patients with bladder cancer remains uncertain. Retrospective studies have given conflicting results. Although one study initially suggested that statins may be harmful in patients receiving BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/99\">",
"     99",
"    </a>",
"    ], two other studies found no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Furthermore, a fourth study in patients with more advanced bladder cancer suggested that these agents might have antitumor effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTRAVESICAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no agent has been shown to be superior to BCG in head to head studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/65-68\">",
"     65-68",
"    </a>",
"    ], single-dose intravesical chemotherapy, given in the immediate post-operative period for low-risk papillary disease, does have a clear role. A meta-analysis of seven randomized trials that included 1476 patients found a statistically significant decrease in the risk of recurrence (48 versus 37 percent, odds ratio 0.61) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/103\">",
"     103",
"    </a>",
"    ]. Agents that have been evaluated in the trials included in the meta-analysis were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    , and pirarubicin.",
"   </p>",
"   <p>",
"    An even greater absolute reduction (about 17 percent) was observed for patients with multifocal tumors, but this was felt to be insufficient therapy, since 65 percent of patients still recurred. For patients with low-grade disease that has previously recurred or is multifocal, six weekly courses of intravesical chemotherapy is considered a reasonable alternative to BCG for initial management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/41\">",
"     41",
"    </a>",
"    ]. Failure on such a regimen does not appear to adversely affect subsequent response to BCG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Mitomycin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    has been used with multiple schedules, including single dose, multiple weekly administrations, or with a maintenance regimen. Mitomycin is the most commonly used intravesical chemotherapeutic agent, although the optimal schedule is not known and it has not been approved by the Food and Drug Administration for intravesical use.",
"   </p>",
"   <p>",
"    In a meta-analysis that was included in the American Urological Association guidelines, a single dose post-operative instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    provided an average absolute benefit of a 17 percent reduction in early tumor recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    with extended maintenance therapy was illustrated in a multicenter trial in which 495 patients were randomly assigned to intravesical therapy with BCG (weekly for six doses), mitomycin (20 mg weekly for six weeks), or mitomycin (20 mg weekly for six weeks, then monthly for three years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/104\">",
"     104",
"    </a>",
"    ]. The three-year recurrence-free rates with six-week courses of either BCG or mitomycin were inferior to that achieved with maintenance mitomycin (66 and 69 percent versus 86 percent).",
"   </p>",
"   <p>",
"    Other randomized trials have suggested improved results with a variety of approaches to enhance the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    . These approaches have included an \"optimized\" regimen using a longer dwell time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/105\">",
"     105",
"    </a>",
"    ], increasing the intravesical drug concentration by decreasing the volume in which the drug is instilled (40 mg in 20 cc), decreasing urine volume by dehydration and complete emptying, and by alkalinizing the urine to stabilize the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/106\">",
"     106",
"    </a>",
"    ], electromotive instillation to accelerate drug delivery into and across biologic membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/107\">",
"     107",
"    </a>",
"    ], and microwave hyperthermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/108\">",
"     108",
"    </a>",
"    ]. The optimized regimen was proven superior to standard administration of 20 mg diluted in 20 cc volume in a randomized clinical trial, and many have adopted this as the standard of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/106\">",
"     106",
"    </a>",
"    ]. Although the other variations have shown benefits compared to standard intravesical mitomycin or BCG, confirmatory trials are required before they can be adopted as standard therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     Mitomycin",
"    </a>",
"    is an alkylating agent that is minimally absorbed from the bladder into the systemic circulation. As a result, myelosuppression following the intravesical use of this agent is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other toxicities which have been reported following intravesical administration include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A self-limited chemical cystitis has been reported in approximately 40 percent of patients receiving intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/88\">",
"       88",
"      </a>",
"      ]. Only rarely does this progress to shrunken, contracted bladder.",
"     </li>",
"     <li>",
"      A rash primarily involving the palms, soles, and genitalia is thought to be a manifestation of a hypersensitivity reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the chemical cystitis and the rash generally respond to treatment with corticosteroids.",
"   </p>",
"   <p>",
"    In addition, wounds in the bladder do not heal properly once intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    is started. Such areas do not completely epithelialize and can undergo dystrophic calcification. Although usually asymptomatic, these lesions can take months or years to fully resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     Epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22292?source=see_link\">",
"     valrubicin",
"    </a>",
"    are anthracyclines with limited systemic absorption following intravesical instillation. Studies have demonstrated activity for these agents but the role of anthracyclines remains limited.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    is more active than either placebo or interferon (IFN) alfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/23,111,112\">",
"     23,111,112",
"    </a>",
"    ], it was less active than BCG in a trial of 957 patients with intermediate and high-risk Ta and T1 papillary bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/113\">",
"     113",
"    </a>",
"    ]. Patients were randomly assigned to intravesical epirubicin (50 mg weekly for six weeks) or BCG (Tice strain, weekly for six weeks). Both groups then received maintenance treatment with three weekly intravesical doses of either agent every three months for 36 months. Treatment with BCG resulted in a significantly longer time to first recurrence compared to epirubicin and a higher three-year recurrence-free survival (65 versus 49 percent). Furthermore, at a median follow-up of 9.2 years, risks of first recurrence and distant metastases were significantly lower with BCG compared to epirubicin (38 versus 53 percent and 5.0 versus 8.6 percent, respectively); death from all causes and death from bladder cancer were significantly reduced with BCG compared with epirubicin (31 versus 38 percent and 3.4 versus 6.8 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anthracycline",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22292?source=see_link\">",
"     valrubicin",
"    </a>",
"    is approved by the United States Food and Drug Administration (FDA) for intravesical use in patients with Tis lesions who have failed intravesical BCG, and in whom immediate cystectomy is either refused or contraindicated. The efficacy of valrubicin in this setting was supported by a series of 90 patients with recurrent Tis after multiple prior courses of intravesical therapy, including BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/115\">",
"     115",
"    </a>",
"    ]. Each patient received six weekly instillations (800 mg) and was evaluated at three-month intervals following treatment. Complete remission was noted in 19 patients (21 percent). Median time to failure or last follow-up for complete responders was more than 18 months. The main side effects are reversible local bladder symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    has been proposed as an alternative to BCG or for patients who have progressed on BCG based upon results from small, nonrandomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/116-119\">",
"     116-119",
"    </a>",
"    ]. These studies suggest that intravesical gemcitabine is an active agent for patients with muscle invasive bladder cancer. However, further prospective data are needed before gemcitabine can be incorporated as a standard alternative to BCG for non-muscle-invasive bladder cancer.",
"   </p>",
"   <p>",
"    The results were best summarized in a 2012 systematic review of six randomized trials evaluating intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    over placebo or another agent that came to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/120\">",
"     120",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to saline alone, a single postoperative treatment of intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No significant effect on recurrence rate (28 versus 39 percent, respectively)",
"     </li>",
"     <li>",
"      No significant difference on recurrence-free survival (hazard ratio [HR] for recurrence 0.95, 95% CI 0.64-1.39)",
"     </li>",
"     <li>",
"      A higher rate of progression to invasive disease (2.4 versus 0.8 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C, intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A lower rate of recurrence (28 versus 39 percent, respectively) that did not reach statistical significance",
"     </li>",
"     <li>",
"      A lower rate of disease progression (11 versus 18 percent) that was not statistically significant",
"     </li>",
"     <li>",
"      A significantly lower incidence of adverse events (39 versus 72 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to intravesical BCG, intravesicular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was associated with different outcomes depending on the patient population enrolled:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In untreated patients with Ta-T1 bladder tumors without carcinoma in situ, intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was equivalent to intravesical BCG in terms of recurrence rates (25 versus 30 percent, respectively) and risk of progression. However, compared to intravesical BCG, it was associated with significantly less dysuria (13 versus 45 percent) and frequency (10 versus 45 percent).",
"     </li>",
"     <li>",
"      In high risk patients, intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was associated with a significantly higher recurrence rate (53 versus 28 percent with intravesical BCG) and a significantly shorter time to recurrence (26 versus 39 months, respectively).",
"     </li>",
"     <li>",
"      In patients with progression after BCG, compared to continued BCG treatment, intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      resulted in significantly fewer recurrences (52 versus 88 percent) and a statistically non-significant increase in the time to recurrence (4 versus 3 months). The rate of progression for continued BCG and gemcitabine was similar (38 versus 33 percent, respectively). A similar rate of moderate to serious (grade",
"      <span class=\"nowrap\">",
"       2/3)",
"      </span>",
"      toxicity was also reported.",
"     </li>",
"     <li>",
"      In patients with progression after BCG, multiple treatments with intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was associated with a greater response compared to single dose treatment (36 percent with three bi-weekly doses and 40 percent with six weekly doses, versus 9 percent as a single dose instillation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these results suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is better tolerated than other agents; however, its effect on clinically important outcomes is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNs directly inhibit the proliferation of bladder tumor cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/121\">",
"     121",
"    </a>",
"    ] and increase bladder tumor cell surface antigen expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/122\">",
"     122",
"    </a>",
"    ]. This improved antigenic recognition of tumor cells, as well as the antiproliferative and immunostimulatory effects of IFN may account for their activity in bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies using intravesical instillations of IFN alfa (IFNa) reported that treatment was well tolerated and associated with a dose-related decrease in the recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. However, randomized trials comparing IFNa with either BCG or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    have shown that it has less activity than either of those agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/111,126\">",
"     111,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large phase III trial, 670 patients were randomly assigned to BCG alone or BCG plus intravesical IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/127\">",
"     127",
"    </a>",
"    ]. All patients had newly-diagnosed, histologically confirmed non-muscle-invasive bladder cancer and had not received prior BCG. Patients were simultaneously randomized to recommended daily allowance vitamins or megavitamins. There was no evidence of any reduction in the rate of bladder recurrence associated with the addition of IFNa to BCG, nor was there any benefit attributable to the megadose vitamins.",
"   </p>",
"   <p>",
"    A multicenter phase II trial has suggested that some patients who recurr on BCG alone may respond if retreated with the combination of BCG plus IFNa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/128\">",
"     128",
"    </a>",
"    ]. However, there are no randomized trials that have confirmed a benefit from combination therapy in this setting.",
"   </p>",
"   <p>",
"    IFNa has not been approved for intravesical use in patients with bladder cancer but is commonly used off-label.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Thiotepa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     Thiotepa",
"    </a>",
"    was the first intravesical agent to be used for non-muscle invasive bladder cancer. A randomized trial conducted by the National Bladder Cancer Collaborative Group showed that intravesical thiotepa (30 or 60 mg) was associated with a significant reduction in recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/129\">",
"     129",
"    </a>",
"    ]. However, it can cause irritative voiding symptoms in up to 69 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its relatively small molecular weight (186 daltons),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    is absorbed systemically, and the incidence of myelosuppression may be as high as 54 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/109,130\">",
"     109,130",
"    </a>",
"    ]. Furthermore, thiotepa is a potent carcinogen and has been linked to the development of secondary leukemia in patients treated for non-muscle invasive bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these acute side effects and late complications, intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    is seldom used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    may have activity in patients with nonmuscle invasive urothelial bladder cancer that is refractory to BCG. In a phase I study of 18 patients, four (22 percent) remained disease-free at a median follow-up of 48 months following one course of six weekly intravesical installations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. The addition of monthly maintenance therapy, however, improved the 13-month disease free outcome to 44 percent (6 of 13 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several novel approaches have been evaluated to decrease the incidence of recurrence following initial treatment for non-muscle invasive bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its use in the initial management of patients with non-muscle invasive bladder cancer, photodynamic therapy using the photosensitizing agents 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    (Photofrin) may have a role in patients with refractory non-muscle invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/135-138\">",
"     135-138",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Fluorescence endoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Results from the two largest series are summarized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 31 patients with recurrent disease who were followed for 24 months after intravesical application of ALA and transurethral light exposure, 16 were free of tumor recurrence, including four of ten patients with prior BCG treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/135\">",
"       135",
"      </a>",
"      ]. Treatment was well tolerated.",
"     </li>",
"     <li>",
"      Long-term benefit was suggested in a series of 34 patients with refractory Tis (n = 29) or multiple small papillary Ta or T1 lesions (n = 5) who underwent therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39157?source=see_link\">",
"       porfimer",
"      </a>",
"      followed by transurethral light exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/138\">",
"       138",
"      </a>",
"      ]. At three months, a complete or partial response was achieved by 14 and 4 patients, respectively, while 14 were nonresponders (including four of five patients with",
"      <span class=\"nowrap\">",
"       Ta/T1",
"      </span>",
"      disease). With a median follow-up of 52 months, only three complete responders required cystectomy for progressive disease (mean time 20 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Photodynamic therapy remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy (RT), with or without platinum-based chemotherapy, has been evaluated as an alternative to intravesical therapy for patients with high-grade T1 lesions following TURBT.",
"   </p>",
"   <p>",
"    In this setting, RT alone does not appear to have a role. In a randomized trial of 210 patients with high-grade T1NXMO disease, radical RT (60 Gy in 30 fractions) alone had no advantages over observation in terms of progression-free or overall survival for patients with unifocal disease, or over BCG for those with multifocal disease or CIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible role for RT as part of a combined modality approach including chemotherapy for treatment of patients with muscle invasive cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41992?source=see_link&amp;anchor=H501917562#H501917562\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\", section on 'Primary chemoradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemopreventive biologic agents rather than or in addition to intravesical therapy have been evaluated to prevent recurrence of low-risk non-muscle invasive bladder cancers. Although some data supporting these agents are suggestive, no role has been established for any chemopreventive agent in patients with previously treated non-muscle invasive bladder cancer.",
"   </p>",
"   <p>",
"    Chemopreventive agents to prevent recurrence are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35367?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention of bladder cancer\", section on 'Chemopreventive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     POSTTREATMENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful follow-up is required for both high- and low-risk patients with non-muscle invasive bladder cancer. Recurrent disease can develop anywhere along the genitourinary epithelium, including the renal pelvis, ureters, and urethra, as well as the bladder. One consequence of the \"successful\" treatment of tumors in the bladder has been an increase in the frequency of extravesical recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/140\">",
"     140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10664?source=see_link\">",
"     \"Urethral cancer in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34357?source=see_link\">",
"     \"Urethral cancer in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be encouraged to discontinue smoking, because of the association between smoking and urothelial cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the basis of an ongoing drug safety review, the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/ucm259150.htm\">",
"     Food and Drug Administration",
"    </a>",
"    has recommended against the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    in patients with active bladder cancer or in patients with a history of bladder cancer. Further information is discussed separately. An association between the use of pioglitazone and bladder cancer, particularly in patients receiving &gt;24 months of therapy, has been suggested in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     \"Pioglitazone: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Cystoscopy and cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up evaluation with repeat cystoscopy and urinary cytology is necessary three months after therapy. If the bladder is not endoscopically and cytologically free of tumor, a repeat course of intravesical therapy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/143\">",
"     143",
"    </a>",
"    ]. Cystectomy should be considered for patients with recurrent or persistent tumor after one or two cycles of intravesical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no recurrences are documented, repeat urinalysis and cystoscopy are generally advised at three to six month intervals, depending on the number of tumor recurrences, for the first four years and annually thereafter in the absence of tumor recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence to surveillance recommendations is often suboptimal, as illustrated in a series of 6717 patients aged 65 or older with non-muscle invasive bladder cancer identified in the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database of the National Cancer Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/146\">",
"     146",
"    </a>",
"    ]. During the five contiguous six-month intervals following initial diagnosis, only 40 percent of patients had an examination during all five periods, while 18 percent were examined during two or fewer of these periods. Among the factors that were independently associated with a lower intensity of surveillance were age &ge;75 years, nonwhite ethnicity, favorable tumor histology (ie, well-differentiated versus poorly differentiated), and a high degree of comorbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Urine biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of urinary biomarkers are being evaluated for their utility in surveillance following initial treatment of non-muscle invasive bladder cancer.",
"   </p>",
"   <p>",
"    In the United States several of these urine tests (eg, bladder tumor antigen [BTA] Stat, BTA TRAK, UroVysion, nuclear matrix protein [NMP] 22) are approved for the detection of tumor recurrence. However, none of these tests has been proven to have sufficient diagnostic reliability to eliminate the need for cystoscopy. Major problems with these assays include the lack of sensitivity for small tumors, particularly low-grade lesions, as well as a large number of false positives.",
"   </p>",
"   <p>",
"    The data supporting the use of these assays and their potential role in bladder cancer surveillance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40041?source=see_link&amp;anchor=H3#H3\">",
"     \"Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder\", section on 'Urine biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Imaging of the urinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;In large series the incidence of renal pelvis and ureteral tumors has ranged from 1 to 4 percent, although a substantially higher incidence has been reported in small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/147-153\">",
"     147-153",
"    </a>",
"    ]. The median time to discovery of such tumors following the diagnosis of bladder cancer has varied from three to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/147,148,151,152\">",
"     147,148,151,152",
"    </a>",
"    ]. &nbsp;Factors that may increase the risk of developing an upper tract tumor include urethral involvement, vesicoureteral reflux, the presence of multiple tumors or Tis, previous BCG treatment, and occupational exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/148,149,151-153\">",
"     148,149,151-153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link&amp;anchor=H9#H9\">",
"     \"Malignancies of the renal pelvis and ureter\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of imaging (ie, intravenous pyelogram, CT urography, retrograde pyelography, or magnetic resonance imaging (MRI) urogram) is individualized based on the risk for development of an upper tract tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no data to support routine upper tract imaging for patients with single, nonrecurrent, low-grade, small, papillary tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with no obvious intravesical tumor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have positive urinary cytology, we suggest careful periodic evaluation of the upper tracts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/154,155\">",
"       154,155",
"      </a>",
"      ]. CT urography has replaced IVP as the preferred imaging modality in this situation. This may be combined with ureteroscopy for any suspicious lesions.",
"     </li>",
"     <li>",
"      For patients with intermediate to high-risk disease after TURBT and a negative urine cytology, we suggest imaging of the upper urinary tracts every one to two years is recommended to exclude involvement with metachronous lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/145,154,156\">",
"       145,154,156",
"      </a>",
"      ]. This should be continued for five years in patients with intermediate-risk disease and for life in patients with high-risk disease. Imaging options include. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H388504742\">",
"    <span class=\"h2\">",
"     Evaluation of the prostatic urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to bladder and upper urinary tract recurrences, tumor recurrences in the prostatic urethra and ducts are not uncommon. In a series of 186 men followed for 15 years, 39 percent had a relapse in the prostatic urethra, with 15 percent showing stromal invasion of the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/157\">",
"     157",
"    </a>",
"    ]. More than one-half of the relapses occurred in the first five years, but 39 percent were diagnosed between 5 and 15 years. A high index of suspicion is needed for early diagnosis of a urethral recurrence with the most common symptom being urinary tract obstruction. Patients suspected of urethral metastases require cystourethroscopy and retrograde urethrography. A further discussion of urethral cancer in men is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10664?source=see_link\">",
"     \"Urethral cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Non-muscle invasive papillary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent non-muscle invasive papillary tumors (Ta, (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    )) can generally be managed with repeat TURBT. Although this is typically performed with the patient under general anesthesia, office fulguration may be appropriate for selected patients with fewer than five small (&lt;0.5 cm), low-grade lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/158\">",
"     158",
"    </a>",
"    ]. It is even possible to safely monitor these patients initially and intervene when size or symptoms dictate in patients with an established pattern of low-grade recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Tis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tis (carcinoma in situ) cannot be controlled with TURBT alone. If intravesical therapy fails to control disease, cystectomy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/160\">",
"     160",
"    </a>",
"    ]. While both standard and novel therapies have been used for patients who have refused cystectomy or are not candidates for surgical resection, there is a real danger of progression when definitive treatment is delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/161\">",
"     161",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     T1 disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse with recurrent T1 tumors within six months to one year after TURBT and one or two courses of BCG are best treated with cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/91,162\">",
"     91,162",
"    </a>",
"    ]. In an analysis based upon a comparison with a historical cohort, preemptive radical cystectomy was associated with better disease-specific survival than postponing cystectomy until the appearance of T2 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/163\">",
"     163",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Salvage cystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of salvage cystectomy is controversial. The potential benefits of preserving the bladder must be balanced against the risks of developing metastatic disease and thus decreased survival.",
"   </p>",
"   <p>",
"    Intravesical therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22292?source=see_link\">",
"     valrubicin",
"    </a>",
"    or BCG plus interferon may avoid or delay cystectomy, particularly in patients who represent a poor medical risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/164,165\">",
"     164,165",
"    </a>",
"    ]. In one report of 40 patients who had failed one (19) or more (21) induction courses of intravesical BCG, weekly low-dose BCG (one-third dose, or 27 mg) plus interferon-alpha 2b (50 million units) was administered for six to eight weeks and repeated at months 5, 11, and 17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/165\">",
"     165",
"    </a>",
"    ]. At 12 and 24 months, 63 and 53 percent of patients were disease-free, respectively, and 12 of 22 patients who were initially planned for cystectomy were cystoscopically disease-free with an intact bladder.",
"   </p>",
"   <p>",
"    However, other data suggest inferior survival in patients who are treated with continued bladder-sparing strategies and delayed cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/11/40122/abstract/166\">",
"     166",
"    </a>",
"    ]. This was illustrated by a report of 90 patients with high-risk non-muscle invasive bladder tumors who underwent salvage cystectomy. The indication for cystectomy was refractory or recurrent non-muscle invasive disease in 35 and progression with either muscle-invasive disease or prostatic stromal invasion in 55. The survival rate was significantly better for patients undergoing cystectomy less than one year after BCG therapy (75 versus 34 percent for delayed cystectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial diagnosis and management of patients with non-muscle-invasive bladder tumors (Ta, Tis, and T1, (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      )) generally includes a complete cystoscopic transurethral resection of the bladder tumor (TURBT). An examination under anesthesia (EUA) should be performed at the same time. For patients with non-muscle invasive disease, TURBT, often in conjunction with intravesical chemotherapy or immunotherapy, may delay or avoid the need for radical cystectomy. Subsequent management requires a consideration of the risk of recurrence or progression as estimated based upon clinical factors. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Transurethral resection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"       \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at low risk of recurrence following TURBT, we recommend an immediate, single post-operative dose of chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This is considered sufficient in itself without the need for additional therapy, and BCG is never given in this setting. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intravesical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most extensive data for intravesical chemotherapy are with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Mitomycin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients at intermediate risk of recurrence following TURBT, we recommend postoperative adjuvant intravesical therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This therapy should include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An immediate single post-operative dose of chemotherapy followed by either an induction cycle of further chemotherapy or BCG. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intravesical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have failed prior intravesical chemotherapy, further therapy in the form of BCG is indicated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intravesical BCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those given induction BCG, we recommend that maintenance BCG should be continued for at least one year (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with stage T1 tumors (and select patients with Tis or Ta tumors in whom original staging was inadequate), we recommend a course of intravesical BCG immunotherapy following a restaging TURBT rather than intravesical chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intravesical BCG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients given intravesical BCG immunotherapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The initial course of BCG immunotherapy generally consists of six weekly doses of BCG. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance BCG therapy, treatment should be continued for at least one year if possible. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Posttreatment management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize the risk of systemic infection, intravesical BCG should not be administered to patients with traumatic catheterization, active cystitis, or persistent gross hematuria following TURBT. BCG is never given in the perioperative setting. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=see_link\">",
"       \"Complications of intravesical BCG immunotherapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients being treated for non-muscle invasive bladder cancer, careful surveillance with cystoscopy and cytology is required and should begin three months after the initiation of BCG therapy. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Cystoscopy and cytology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If no evidence of disease is found at the three-month evaluation, a reasonable surveillance schedule includes repeat cystoscopy and urine cytology at three month intervals for two years, at six month intervals for another two years, and then annually thereafter. Selected patients with low risk disease may be followed with a less intensive schedule. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Cystoscopy and cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the risk of metachronous involvement of the upper urinary tract, surveillance should include imaging of the upper urinary tracts every one to two years for all but the lowest risk patients. This should be continued for five years in patients with intermediate-risk disease and for life in patients with high-risk disease. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Cystoscopy and cytology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with residual non-muscle invasive disease at the three-month cystoscopy or a subsequent recurrence with non-muscle invasive disease after failing BCG, we suggest another six-week course of either intravesical BCG or BCG plus interferon (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients whose initial treatment consisted of intravesical chemotherapy and who recur without interval disease progression, we recommend a trial of intravesical BCG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Cystoscopy and cytology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with high-risk residual non-muscle invasive disease after two initial courses of intravesical BCG and for those requiring multiple courses of intravesical BCG over time, we suggest that cystectomy be strongly considered (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"       \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with recurrent CIS after two courses of BCG, we recommend cystectomy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For patients who refuse cystectomy or who are too ill for major surgery, alternative methods may be considered but at the risk for interval disease progression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"       \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/2\">",
"      Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/3\">",
"      Holm&auml;ng S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/4\">",
"      Bostwick DG. Natural history of early bladder cancer. J Cell Biochem Suppl 1992; 16I:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/5\">",
"      Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/6\">",
"      Pagano F, Garbeglio A, Milani C, et al. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 1987; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/7\">",
"      Tilki D, Reich O, Svatek RS, et al. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol 2010; 183:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/8\">",
"      Chade DC, Shariat SF, Godoy G, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 2010; 184:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/9\">",
"      Wallace DM, Hindmarsh JR, Webb JN, et al. The role of multiple mucosal biopsies in the management of patients with bladder cancer. Br J Urol 1979; 51:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/10\">",
"      Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 1977; 37:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/11\">",
"      Herr HW, Jakse G, Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/12\">",
"      Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004; 93:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/13\">",
"      Alkhateeb SS, Van Rhijn BW, Finelli A, et al. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010; 184:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/14\">",
"      Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/15\">",
"      Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/16\">",
"      Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/17\">",
"      Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/18\">",
"      Lutzeyer W, R&uuml;bben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/19\">",
"      Torti FM, Lum BL, Aston D, et al. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 1987; 5:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/20\">",
"      Mariappan P, Smith G, Lamb AD, et al. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol 2007; 177:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/21\">",
"      Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008; 54:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/22\">",
"      Lerman RI, Hutter RV, Whitmore WF Jr. Papilloma of the urinary bladder. Cancer 1970; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/23\">",
"      Oosterlinck W, Kurth KH, Schr&ouml;der F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/24\">",
"      Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/25\">",
"      Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006; 27:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/26\">",
"      van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/27\">",
"      Hern&aacute;ndez S, L&oacute;pez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/28\">",
"      Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/29\">",
"      Moonen PM, van Balken-Ory B, Kiemeney LA, et al. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007; 177:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/30\">",
"      Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009; 182:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/31\">",
"      Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/32\">",
"      Dyrskj&oslash;t L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007; 13:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/33\">",
"      Allard P, Bernard P, Fradet Y, T&ecirc;tu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/34\">",
"      Mill&aacute;n-Rodr&iacute;guez F, Ch&eacute;chile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/35\">",
"      Kiemeney LA, Witjes JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/36\">",
"      Holm&auml;ng S, Hedelin H, Anderstr&ouml;m C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999; 162:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/37\">",
"      Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000; 7:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/38\">",
"      Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.eortc.be/tools/bladdercalculator/default.htm. (Accessed on February 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/40\">",
"      Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/41\">",
"      Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/42\">",
"      Thrasher JB, Frazier HA, Robertson JE, Paulson DF. Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 1994; 152:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/43\">",
"      Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/44\">",
"      Lee SE, Jeong IG, Ku JH, et al. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor. Urology 2004; 63:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/45\">",
"      Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005; 174:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/46\">",
"      Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/47\">",
"      Kl&auml;n R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/48\">",
"      Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002; 60:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/49\">",
"      Louhelainen J, Wijkstr&ouml;m H, Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int J Cancer 2000; 87:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/50\">",
"      Grimm MO, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/51\">",
"      Andius P, Holm&auml;ng S. Bacillus Calmette-Gu&eacute;rin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004; 93:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/52\">",
"      Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/53\">",
"      Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010; 57:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/54\">",
"      Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/55\">",
"      Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/56\">",
"      Filbeck T, Roessler W, Knuechel R, et al. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999; 13:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/57\">",
"      Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; 171:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/58\">",
"      Hungerhuber E, Stepp H, Kriegmair M, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007; 69:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/59\">",
"      Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/60\">",
"      Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/61\">",
"      Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/62\">",
"      Schumacher MC, Holm&auml;ng S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/63\">",
"      Stenzl A, Penkoff H, Dajc-Sommerer E, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/64\">",
"      Lee CT, Dunn RL, Ingold C, et al. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology 2007; 69:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/65\">",
"      Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/66\">",
"      Mart&iacute;nez-Pi&ntilde;eiro JA, Jim&eacute;nez Le&oacute;n J, Mart&iacute;nez-Pi&ntilde;eiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/67\">",
"      Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003; :CD003231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/68\">",
"      B&ouml;hle A, Bock PR. Intravesical bacille Calmette-Gu&eacute;rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/69\">",
"      de Reijke TM, Kurth KH, Sylvester RJ, et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol 2005; 173:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/70\">",
"      Prescott S, Jackson AM, Hawkyard SJ, et al. Mechanisms of action of intravesical bacille Calmette-Gu&eacute;rin: local immune mechanisms. Clin Infect Dis 2000; 31 Suppl 3:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/71\">",
"      B&ouml;hle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/72\">",
"      Mungan NA, Witjes JA. Bacille Calmette-Gu&eacute;rin in superficial transitional cell carcinoma. Br J Urol 1998; 82:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/73\">",
"      Durek C, Richter E, Basteck A, et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol 2001; 165:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/74\">",
"      Jackson A, Alexandroff A, Fleming D, et al. Bacillus-calmette-guerin (bcg) organisms directly alter the growth of bladder-tumor cells. Int J Oncol 1994; 5:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/75\">",
"      Catalona WJ, Ratliff TL. Bacillus Calmette-Gu&eacute;rin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu 1990; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/76\">",
"      Mart&iacute;nez-Pi&ntilde;eiro JA, Mart&iacute;nez-Pi&ntilde;eiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/77\">",
"      Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/78\">",
"      Agrawal MS, Agrawal M, Bansal S, et al. The safety and efficacy of different doses of bacillus Calmette Gu&eacute;rin in superficial bladder transitional cell carcinoma. Urology 2007; 70:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/79\">",
"      Shelley MD, Court JB, Kynaston H, et al. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev 2000; :CD001986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/80\">",
"      Lerner SP, Tangen CM, Sucharew H, et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/81\">",
"      Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu&eacute;rin therapy of superficial bladder cancer. J Clin Oncol 1987; 5:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/82\">",
"      Palou J, Laguna P, Mill&aacute;n-Rodr&iacute;guez F, et al. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001; 165:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/83\">",
"      Hudson MA, Ratliff TL, Gillen DP, et al. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/84\">",
"      Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette-Gu&eacute;rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995; 75:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/85\">",
"      Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/86\">",
"      Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette-Gu&eacute;rin maintenance therapy for superficial bladder cancer. Urology 2001; 57:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/87\">",
"      Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/88\">",
"      B&ouml;hle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/89\">",
"      Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987; 137:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/90\">",
"      Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/91\">",
"      Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/92\">",
"      Brake M, Loertzer H, Horsch R, Keller H. Long-term results of intravesical bacillus Calmette-Gu&eacute;rin therapy for stage T1 superficial bladder cancer. Urology 2000; 55:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/93\">",
"      Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Gu&eacute;rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/94\">",
"      Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 2002; 167:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/95\">",
"      Margel D, Tal R, Golan S, et al. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Gu&eacute;rin immunotherapy. Urology 2007; 69:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/96\">",
"      Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Safety and efficacy of intravesical bacillus Calmette-Gu&eacute;rin plus interferon &alpha;-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. J Urol 2010; 184:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/97\">",
"      Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/98\">",
"      Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/99\">",
"      Hoffmann P, Roumegu&egrave;re T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006; 355:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/100\">",
"      Orsola A, Cecchini L, Bellmunt J. Statins and the effect of BCG on bladder cancer. N Engl J Med 2007; 356:1276; author reply 1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/101\">",
"      Berglund RK, Savage CJ, Vora KC, et al. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 2008; 180:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/102\">",
"      Tsai HK, Katz MS, Coen JJ, et al. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology 2006; 68:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/103\">",
"      Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/104\">",
"      Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu&eacute;rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007; 52:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/105\">",
"      Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) 1988; 296:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/106\">",
"      Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001; 93:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/107\">",
"      Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011; 12:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/108\">",
"      Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21:4270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/109\">",
"      Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/110\">",
"      Colver GB, Inglis JA, McVittie E, et al. Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction? Br J Dermatol 1990; 122:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/111\">",
"      Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III. J Urol 1999; 161:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/112\">",
"      Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008; 179:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/113\">",
"      van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/114\">",
"      Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu&eacute;rin, and bacillus Calmette-Gu&eacute;rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/115\">",
"      Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/116\">",
"      Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/117\">",
"      G&aring;rdmark T, Carringer M, Beckman E, et al. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 2005; 66:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/118\">",
"      Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Gu&eacute;rin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/119\">",
"      Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 2008; 26:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/120\">",
"      Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 2012; 1:CD009294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/121\">",
"      Borden EC, Groveman DS, Nasu T, et al. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1984; 132:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/122\">",
"      Hawkyard S, James K, Prescott S, et al. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol 1991; 145:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/123\">",
"      Sargent ER, Williams RD. Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin. Urol Clin North Am 1992; 19:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/124\">",
"      Giannakopoulos S, Gekas A, Alivizatos G, et al. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998; 82:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/125\">",
"      O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004; 172:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/126\">",
"      Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Gu&eacute;rin and interferon-alpha. Urology 1997; 50:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/127\">",
"      Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Gu&eacute;rin with or without interferon &alpha;-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010; 184:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/128\">",
"      Joudi FN, Smith BJ, O'Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu&eacute;rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006; 24:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/129\">",
"      Prout GR Jr, Koontz WW Jr, Coombs LJ, et al. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983; 130:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/130\">",
"      Hollister D Jr, Coleman M. Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. JAMA 1980; 244:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/131\">",
"      Silberberg JM, Zarrabi MH. Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature. J Urol 1987; 138:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/132\">",
"      McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006; 24:3075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/133\">",
"      Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 2010; 75:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/134\">",
"      Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Gu&eacute;rin therapy. BJU Int 2009; 104:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/135\">",
"      Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003; 61:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/136\">",
"      Kriegmair M, Baumgartner R, Lumper W, et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996; 77:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/137\">",
"      Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001; 165:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/138\">",
"      Manyak MJ, Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol 2003; 17:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/139\">",
"      Harland SJ, Kynaston H, Grigor K, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007; 178:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/140\">",
"      Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998; 16:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/141\">",
"      Stephenson J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA 2011; 306:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/142\">",
"      Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/143\">",
"      Herr HW, Badalament RA, Amato DA, et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/144\">",
"      Hall RR, Parmar MK, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994; 308:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/145\">",
"      Evans CP. Follow-up surveillance strategies for genitourinary malignancies. Cancer 2002; 94:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/146\">",
"      Schrag D, Hsieh LJ, Rabbani F, et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/147\">",
"      Sanderson KM, Cai J, Miranda G, et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol 2007; 177:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/148\">",
"      Schwartz CB, Bekirov H, Melman A. Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma. Urology 1992; 40:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/149\">",
"      Hurle R, Losa A, Manzetti A, Lembo A. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology 1999; 53:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/150\">",
"      Canales BK, Anderson JK, Premoli J, Slaton JW. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol 2006; 175:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/151\">",
"      Wright JL, Hotaling J, Porter MP. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. J Urol 2009; 181:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/152\">",
"      Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996; 156:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/153\">",
"      Miller EB, Eure GR, Schellhammer PF. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology 1993; 42:26.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/155\">",
"      Schwalb MD, Herr HW, Sogani PC, et al. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence. J Urol 1994; 152:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/156\">",
"      Rabbani F, Perrotti M, Russo P, Herr HW. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 2001; 19:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/157\">",
"      Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol 1999; 161:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/158\">",
"      Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 2004; 171:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/159\">",
"      Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003; 170:438.",
"     </a>",
"    </li>",
"    <li>",
"     Witjes JA, Debruyne FM. Intravesical chemotherapy. In: Genitourinary Oncology, 2nd, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds), Lipincott, Philadelphia 2000. p.394.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/161\">",
"      O'Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol 2006; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/162\">",
"      Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol 2002; 41:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/163\">",
"      Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007; 177:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/164\">",
"      Luciani LG, Neulander E, Murphy WM, Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 2001; 58:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/165\">",
"      O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001; 166:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/11/40122/abstract/166\">",
"      Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166:1296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2996 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40122=[""].join("\n");
var outline_f39_11_40122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Ta tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Tis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - T1 lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multicentricity and frequency of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transurethral resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Restaging TURBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluorescence endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications for cystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Non-muscle invasive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - T1 tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INTRAVESICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INTRAVESICAL BCG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Interactions with statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTRAVESICAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Mitomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Thiotepa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      EXPERIMENTAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      POSTTREATMENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Cystoscopy and cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Urine biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Imaging of the urinary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H388504742\">",
"      Evaluation of the prostatic urethra",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      TREATMENT OF RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Non-muscle invasive papillary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Tis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      T1 disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Salvage cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35367?source=related_link\">",
"      Chemoprevention of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31096?source=related_link\">",
"      Complications of intravesical BCG immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=related_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=related_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=related_link\">",
"      Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=related_link\">",
"      Pioglitazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/26/10664?source=related_link\">",
"      Urethral cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34357?source=related_link\">",
"      Urethral cancer in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40041?source=related_link\">",
"      Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_11_40123="Criteria for dyssynergic defecation";
var content_f39_11_40123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for dyssynergic defecation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        Patients must satisfy the diagnostic criteria for functional chronic constipation (Rome III)",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B.",
"        </strong>",
"        Patients must demonstrate dyssynergia during repeated attempts to defecate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Dyssynergic or obstructive pattern of defecation (types 1-4) is defined as:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Paradoxical increase in anal sphincter pressure (anal contraction)",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Less than 20 percent relaxation of the resting anal sphincter pressure",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Inadequate propulsive forces observed with manometry, imaging, or EMG recordings",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        One or more of the following criteria during repeated attempts to defecate:",
"        <ul>",
"         <li>",
"          Inability to expel an artificial stool (50 mL water-filled balloon) within 1 minute",
"         </li>",
"         <li>",
"          A prolonged colonic transit time (ie, greater than five markers [&gt;20 percent marker retention]) on a plain abdominal radiograph taken 120 hours after ingestion of one sitzmark capsule containing 24 radiopaque markers",
"         </li>",
"         <li>",
"          Inability to evacuate or &ge;50 percent retention of barium during defecography",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Rao SSC. Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin N Am 2008; 37:569. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40123=[""].join("\n");
var outline_f39_11_40123=null;
var title_f39_11_40124="Funct assess questionnaires";
var content_f39_11_40124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used functional assessment questionnaires",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Questionnaire",
"       </td>",
"       <td class=\"subtitle1\">",
"        URL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        General functional assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Health Assessment Questionnaire",
"       </td>",
"       <td>",
"        www.chcr.brown.edu/pcoc/EHAQDESCRSCORINGHAQ372.PDF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Functional Activities Questionnaire",
"       </td>",
"       <td>",
"        https://aviviahealth.com/media/pdf/elder-care/functional-activities-assessment-tool.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SF-36 Physical Functioning Scale",
"       </td>",
"       <td>",
"        www.sf-36.org/tools/SF36.shtml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pain Disability Index",
"       </td>",
"       <td>",
"        www.chronicpainnetwork.com/pdf/Pain_Disability_Index.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        McGill Pain Questionnaire",
"       </td>",
"       <td>",
"        www.chcr.brown.edu/pcoc/MCGILLPAINQUEST.PDF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical Outcomes Study Pain Measures (MOS)",
"       </td>",
"       <td>",
"        www.columbia.edu/cu/ssw/projects/pmap/docs/yoshiokamos.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Low back pain questionnaires",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oswestry Disability Questionnaire",
"       </td>",
"       <td>",
"        www.tac.vic.gov.au/upload/Oswestry.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quebec Back Pain Disability Scale",
"       </td>",
"       <td>",
"        www.oxfordphysicaltherapy.com/media/Quebec-Back-Pain.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Roland Morris Disability Questionnaire",
"       </td>",
"       <td>",
"        file://www.rmdq.org/",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Upper extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DASH (Disabilities of the Arm, Shoulder and Hand)",
"       </td>",
"       <td>",
"        www.dash.iwh.on.ca/assets/images/pdfs/DASH_quest06.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper Extremity Function Scale",
"       </td>",
"       <td>",
"        www.rehabfx.com/upperNEW.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Michigan Hand Outcomes Questionnaire",
"       </td>",
"       <td>",
"        www.cebp.nl/vault_public/filesystem/?ID=1404",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multidimensional Task Ability Profile",
"       </td>",
"       <td>",
"        file://mtapsystems.com/PDF/MTAP_PDC_rev2.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper Extremity Functional Scale (UEFS)",
"       </td>",
"       <td>",
"        file://www.rehabfx.com/upperNEW.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lower extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower Limb Outcomes Questionnaire",
"       </td>",
"       <td>",
"        www.aaos.org/research/outcomes/Lower_Limb.pdf",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MOS 36-item Short-Form Health Survey (SF-36)",
"       </td>",
"       <td>",
"        www.rand.org/health/surveys_tools/mos/mos_core_36item.html#",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40124=[""].join("\n");
var outline_f39_11_40124=null;
var title_f39_11_40125="Meta-regression";
var content_f39_11_40125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Meta-regression of the association between follow-up duration and risk ratio of death in trials of zidovudine monotherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 430px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Decrease in the magnitude of the treatment effect with increasing mean duration of follow-up in studies of zidovudine monotherapy. Studies are represented by dots the size of which is proportional to the inverse of the variance of the observed logarithm of the risk ratio. The depicted regression line is weighted by the inverse of the variance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials 1997; 18:431. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40125=[""].join("\n");
var outline_f39_11_40125=null;
var title_f39_11_40126="Sunrise view patella";
var content_f39_11_40126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sunrise view of the patella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sunrise view of the patella provides a clear view of the patellofemoral joint. It will often reveal fractures not seen on the AP or lateral views.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrice Eiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40126=[""].join("\n");
var outline_f39_11_40126=null;
var title_f39_11_40127="Ballantine clamp";
var content_f39_11_40127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Straight Ballantine clamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ballantine clamp with longitudinal serration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_11_40127=[""].join("\n");
var outline_f39_11_40127=null;
